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ABSTRACT
Semi-invariant natural killer T (iNKT) cells are critical components of the host
immune response in peripheral tissues such as the lung, liver, and gut, and they play
important roles in cancer, bacterial infections, autoimmunity, wound repair, and
atherosclerosis. Tissue-resident iNKT cells exert their effects early in the developing
immune response by rapidly producing a wide variety of cytokines and chemokines, and
it was recently discovered that different tissues possess iNKT cell subsets that
preferentially produce IFN- (NKT1), IL-4 (NKT2), or IL-17 (NKT17). Despite their
critical role in the immune response, the mechanisms that regulate iNKT cell function in
the periphery remain unclear. Signaling lymphocyte activation marker (SLAM) proteins
are cell surface-expressed molecular switches that are expressed on all hematopoietic
cells. The nine SLAM family receptors serve a variety of functions including promotion
of cell-cell adhesion, regulation of cytokine production, co-stimulation, and inhibition.
Importantly, SLAM family receptors are critical for the development of iNKT cells. Yet,
numerous efforts to ascribe discrete roles of SLAM family receptors in iNKT cell
function has proven difficult.
We conducted a comprehensive analysis of SLAM family receptor coexpression on iNKT cell subsets in the lung, spleen, liver, and thymus and identified coexpression profiles that varied in a tissue and strain-dependent manner. Interestingly, we
found that SLAM family receptor expression profiles varied among different iNKT cell
subsets. In particular, we noted a close association of SLAMf6 expression with the NKT2
and NKT17 subsets in both the periphery and in the thymus. Further investigation using
SLAMf6-deficient mice revealed a critical role for SLAMf6 in NKT2 and NKT17 subset
development, and in iNKT IL-4 and IL-17 cytokine production in the periphery. This
investigation also revealed that the SLAMf6high NKT2 and NKT17 subsets exhibited
significantly higher proliferative capacity than the NKT1 subset and the NKT2 and
NKT17 proliferation was dependent, in part, on SLAMf6 expression.
Since Slam family genes are highly polymorphic, we next investigated whether
these polymorphisms regulated iNKT function. We employed a B6.129 congenic mouse
exhibiting impaired NKT cell function, in which a 6.6 Mbp 129/SvJ locus encompassing
Slam genes was introgressed onto the C57BL/6 background. To test the hypothesis that
Slam gene polymorphisms regulate iNKT cell function, we refined this genetic interval
by generating B6.129 subcongenic lines and assessing iNKT cell function. Unexpectedly,
we found that while Slam gene polymorphisms in this model do regulate iNKT cell
function, the dominant regulator was in a 0.14 Mbp interval centromeric to the Slam
genes. Further experimentation revealed that impaired iNKT cell development and
function was associated with changes in the expression of Fcgr3 (Fc gamma receptor III)
on iNKT cells, suggesting it as a novel candidate gene regulating iNKT cell function.
Taken together, these data reveal for the first time a specific role for SLAMf6 on
NKT2 and NKT17 subset development and function. In addition, these data identify
Fcgr3 as a novel candidate gene that regulates iNKT cell subset development and
cytokine production. Cumulatively, these data reveal the presence of discrete regulatory
mechanisms at work in different iNKT subsets, a finding that has broad implications for
our understanding of iNKT-cell mediated immunity.
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CHAPTER 1: COMPREHENSIVE LITERATURE REVIEW

1.1 Introduction to Innate-Like Cells

In introductory Immunology classes, we are taught that there are two arms of the
immune system: the quick responding innate immune system that is triggered within
minutes to hours after infection followed by the more specific adaptive immune system
(Murphy et al., 2012). There are common cells that fit into each of these arms with
dendritic cells, macrophages, neutrophils, and natural killer cells on the innate side, and T
and B cells comprising adaptive immunity (Murphy et al., 2012) (Figure 1-1). Recently,
the definitions of innate and adaptive have become less static, with the discovery of new
subsets of cells comprised of innate lymphoid cells (ILCs) and innate like T cells that
bridge the gap between these two classic arms (Gao and Williams, 2015; Mjosberg and
Spits, 2012). ILCs and innate like T cells are unique in that they can orchestrate a
symphony of immune cell activation allowing the host to combat many different types of
infection, be it bacterial, viral, or parasitic.

1

FIGURE 1-1: Innate and Adaptive Immunity
The quick acting innate immune system is comprised of cells such as neutrophils,
dendritic cells, and macrophages, which aid in antigen presentation or engulfment of
bacteria. The adaptive side is comprised of conventional CD4 and CD8 T cells
which respond to specific pathogen peptides, as well as B cells which are important
for antibody production. Innate like T cells, of which NKT cells are a part of, bridge
the gap between the innate an adaptive immune system, rapidly becoming effectors
to combat infection.

Innate-lymphoid cells are comprised of three different types: ILC1, ILC2, and
ILC3 (Cella et al., 2009; Kiessling et al., 1976; Luci et al., 2009). These subsets are
similar to those described for T helper subsets, where ILC1 cells make type 1 cytokines
including the pro-inflammatory IFNγ (Fuchs et al., 2013). ILC2 have a type 2 phenotype
producing IL-4 and IL-13 (Monticelli et al., 2011; Neill et al., 2010), and ILC3 cells
produce IL-17 (Luci et al., 2009). While these cytokines in T helper subsets have been
2

associated with fighting intracellular bacteria, helminth, and extracellular and fungal
infections respectively (Murphy et al., 2012), ILCs are different in that these early waves
of cytokine production activate antigen presenting cells, leading to activation of the
adaptive immune system (Eberl et al., 2015). ILC’s however, are fully innate cells, and
do not have adaptive qualities in that they fail to recognize specific antigens (Colonna,
2018). Innate-like T cells, however, function to bridge that gap.
Innate lymphoid cells and innate-like T cells reside in peripheral tissues where
they participate in site specific immune responses (Dusseaux et al., 2011; Gasteiger et al.,
2015; Hayday and Tigelaar, 2003; Lee et al., 2015). Innate-like T cells are comprised of
natural killer T cells (NKT), gamma-delta T cells (γδT), and the newly described mucosal
associated invariant T (MAIT) cells. These cells patrol mucosal barriers such as the gut
and lung, providing surveillance and direction for other cell types. In most cases, these
innate-like T cells are the first cells to recognize an infection at mucosal sites (Chien et
al., 2014; Kurioka et al., 2016; Van Kaer and Joyce, 2005). Gamma-delta T cells were
first described in 1986 (Bank et al., 1986; Brenner et al., 1987; Saito et al., 1984),
followed by NKT cells in 1987 (Budd et al., 1987; Fowlkes et al., 1987), and MAIT cells
in 2003 (Treiner et al., 2003). While the first innate-like T cells have been recognized for
over 30yrs, little is known about their precise roles in different types of infection and host
immunity. Even less is known about what regulates these cells, and how these
determinants modify the cellular responses of these cells. For example, the ligands for
gamma-delta T cells are yet to be discovered and we still do not understand how NKT
cells are protective in certain bacterial infections, but pathogenic in autoimmune
3

disorders (Brutkiewicz, 2006). The field has only just discovered that MAIT cells are
highly abundant in the human as compared to the mouse model organism (Garner et al.,
2018).
One of the most unique innate-like T cells are invariant natural killer T (NKT)
cells. First described as having low levels of CD3 and a unique conservation of Vβ7 and
Vβ8 chains in the T cell receptor (TCR) (Budd et al., 1987), researchers could not agree
on what these unique cells were for 8 years until the NK1.1 T cell, and later termed
natural killer T cell, in 1995 was defined (Makino et al., 1995). It was shown that these
cells were indeed a separate cell from the previously known innate natural killer cells and
adaptive CD4+/CD8+ conventional T cells. Indeed, NKT cells have markers and killing
capabilities like that of natural killer cells (Yankelevich et al., 1989), but also have the
adaptive quality of MHC-class 1 like restriction (Adachi et al., 1995). Understanding
some of the factors that regulate iNKT cell biology was a major goal of this dissertation.

1.2 Introduction to Natural Killer T cells
Natural killer T cells are restricted to the non-classical MHC molecule CD1d
and exhibit distinct properties of adaptive T cells and fast acting innate natural killer cells
(Adachi et al., 1995; Makino et al., 1995). There are two types of NKT cells, type 1
which use a semi-invariant TCR α chain, and type 2 NKT cells which are less abundant
in number in the mouse and use a more varied TCR α chain (Budd et al., 1987; Rhost et
al., 2012). Type 1 NKT cells, also known as invariant natural killer T cells (iNKT), use
the Vα14/Jα18, Vβ2/Vβ8/Vβ7 semi-invariant TCR (Koseki et al., 1989; Koseki et al.,
4

1990; Porcelli et al., 1993). Throughout this thesis, I will only discuss properties of iNKT
cells.
iNKT cells are considered the first line of defense upon responding to infection
in the peripheral organs such as the spleen, liver, lung, and gut (Crosby and Kronenberg,
2018; Van Kaer and Joyce, 2005). The percentages of iNKT cells circulating in the blood
in a mouse is 0.1%, while the spleen, liver, lung, and gut can yield between 0.5-2%, 1030%, 3-5%, and 10-15% respectively as a percentage of CD45+ cells (Lee et al., 2015;
Rymarchyk et al., 2008). In the human, iNKT cells in circulation are variable, in some
reports measuring 0.1% to 1% of the leukocytes (Bienemann et al., 2011). iNKT cells
become effectors within minutes to hours after activation as evidenced by identification
of cytokines such as IFNγ, IL-4, and TNFα, in the serum 60min after in vivo challenge
(Bendelac and Schwartz, 1991; Christmas et al., 1987; Nishimura et al., 1997). Due to
this rapid response, NKT cells may play the role of “generals of the immune system”
directing and recruiting other immune cells to carry out their respective roles in
combating infection (Carnaud et al., 1999; Hermans et al., 2003; Kitamura et al., 1999).
The rapid production of cytokines is in part due to the fact that iNKT cells have preformed mRNA transcripts for IFNγ, IL-4, and IL-23R and RORγt, the latter two of which
mediate IL-17 production (Rachitskaya et al., 2008; Stetson et al., 2003). The IFNγ
produced by iNKT cells indirectly activates NK cells (Smyth et al., 2002), which aid in
killing cells that the body recognizes as foreign (non-self). NKT cells also activate
dendritic cells through CD40L binding to CD40 on the APC (Fujii et al., 2004).
Activated DCs are then responsible for MHC presentation and activation of conventional
5

adaptive CD4 and CD8 T cells (Kitamura et al., 1999). NKT cells also help B cells to
produce antibodies via the production of IL-4 and increased contact time for the
formation of germinal centers (Kitamura et al., 2000) (Chang et al., 2011). Additionally,
NKT cell production of IL-17 is important for the activation and recruitment of
neutrophils (Li et al., 2007). Thus, cytokine production by NKT cells are important for
the activation of many other cells of the immune system.
In addition to cytokine production, NKT cells are prolific cytotoxic cells (Nicol
et al., 2000). NKT cells make copious amounts of granzyme b and perforin (Nguyen et
al., 2008), and can kill any cells that present a glycolipid on CD1d to the iNKT cell. This
is especially important in cancer models where iNKT cells have been shown to be
important for preventing tumor growth. In a cytotoxicity killing assay, ligation of
NKG2D resulted in increased killing from iNKT cells by degranulation of perforin
(Kuylenstierna et al., 2011). Activation of iNKT cells within the tumor microenvironment
can also trigger NK cells to produce IFNγ, leading to increased NK cell cytotoxicity and
reduced tumor burden (Hayakawa et al., 2002). Thus, iNKT cells serve many roles in the
immune system, be it cytokine production to recruit other cells, or direct or indirect
cytotoxicity.
Importantly, NKT cells develop by fundamentally different mechanisms than
CD4 and CD8 conventional T cells (Bendelac, 1995; Capone et al., 2001). Like
conventional T cells, iNKT cells develop and undergo both positive and negative
selection in the thymus. Selection of iNKT cells occurs via other double positive
thymocytes that express CD1d, not the thymic epithelium as with conventional T cells
6

(Egawa et al., 2005). Early iNKT cell precursors mature into double positive
(CD4posCD8pos) cells, and move through several developmental stages, finally becoming
either CD4pos or CD4neg (Coles and Raulet, 2000). The stages of iNKT cell development
can be identified using the iNKT cell markers CD44 and NK1.1 (Benlagha et al., 2002;
Benlagha et al., 2005). Stage 0 iNKT cells are CD24hiCD44negNK1.1neg. Subsequently,
iNKT

cells

progress

through

Stage

1

CD24lowCD44negNK1.1neg,

Stage

2

CD24lowCD44highNK1.1low, and mature into Stage 3 CD24loCD44highNK1.1high iNKT cells
(Coquet et al., 2008; Gadue and Stein, 2002; Pellicci et al., 2002). Some iNKT cells stay
in the thymus as long-term residents (Berzins et al., 2006), while others emigrate from
the thymus into the periphery, where they gain expression of NK1.1 (McNab et al.,
2005). Recent work has shown diversity and heterogeneity in the subsets of iNKT cells
that remain in the thymus and those that migrate to peripheral tissue, but the signals that
regulate these movements are incompletely understood.

1.3 Activation of NKT cells
Activation of iNKT cells can be achieved by direct CD1d/TCR interactions.
Using the semi-invariant TCR, iNKT cells recognize lipids and glycolipids that are bound
to CD1d (Kawano et al., 1997). There are numerous glycolipids that can bind to CD1d,
each having different length side chains or different head groups (Birkholz et al., 2015;
Tsuji, 2006; Tupin and Kronenberg, 2006). The change in composition or position of the
head groups of said glycolipids alters the avidity of the iNKT cell TCR for the CD1d
molecule (Parekh et al., 2004; Pellicci et al., 2011). For example, alpha7

galactosylceramide, an activator of NKT cells, can bind to the iNKT TCR with a strong
affinity, while β-galactosylceramide has a reduced affinity for the TCR leading to
reduced activation and cytokine production of iNKT cells (Morshed et al., 2009).
Changes in glycolipid configuration and binding to CD1d can therefore have dramatic
effects on iNKT cell responses.
Glycolipids that preferentially activate iNKT cells are derived from self,
commensal bacteria such as Bacteroides fragilis (Wieland Brown et al., 2013), or
pathogenic bacteria such as Streptococcus pneumonia and Borrelia burgdorferi (Godfrey
and Rossjohn, 2011). One of the most potent glycolipid agonists for iNKT cells is alphagalactosylceramide (αGalCer). Originally derived from a sea sponge, and now shown to
be expressed on Bacteroides species, the alpha-galactose head group sits above the CD1d
molecule directly interacting with the iNKT TCR (Morita et al., 1995). The hydrophobic
side chains are buried deep in the CD1d pockets (Koch et al., 2005). The length of the
side chain on the glycolipid can affect how the sugar moiety interacts with the TCR
(Girardi and Zajonc, 2012), changing the avidity of the CD1d/TCR interaction. This
change in the avidity has direct consequences on the magnitude of the iNKT cell cytokine
response, wherein some αGalCer-like molecules induce more IL-4 production while
others attenuate cytokine production (Parekh et al., 2004). Interestingly, the CD1d/TCR
interaction is highly conserved in that αGalCer loaded mouse CD1d can activate human
iNKT cells and vice versa (Brossay et al., 1998). This observation suggests the presence
of strong evolutionary pressure to maintain the recognition of αGalCer or αGalCer-like
compounds by iNKT cells.
8

The second way that iNKT cells can be activated is indirectly from dendritic
cells (DCs) stimulated with TLR ligands such as LPS, self-antigens presented on CD1d,
or by IL-12 and IL-18 produced by activated DCs (Brigl et al., 2003). This activation is
especially important for the iNKT cell response to bacteria that do not have glycolipids
that are directly presented via CD1d. The endogenous pathway allows for iNKT cells to
respond to bacterial invasion from pathogens such as Staphylococcus aureus and
Salmonella typhimurium (Kinjo et al., 2011). IL-12 mediated activation of iNKT cells
has also been shown in response to mouse cyteomegalovirus (MCMV), indicating a role
for iNKT cells in viral infection as well (Wesley et al., 2008) (Tyznik et al., 2014).
Therefore, iNKT cells can be activated in numerous ways to aid in the control of
infection.

1.4 NKT cell TCR Agonists
iNKT cells can be activated by numerous glycolipid antigens. The most wellknown and characterized is αGalCer (Morita et al., 1995). αGalCer, also called
KRN7000, was first derived from an Okinawan sea sponge called Agelas mauritianus,
and was selected initially for use against solid tumors in a B16 melanoma model (Morita
et al., 1995). Initial reports stated that KRN7000 activated dendritic cells (Natori et al.,
1997). It was not until several years later that Kawano et al. reported that KRN7000
specifically activated mouse splenic iNKT cells in a CD1d dependent manner (Kawano et
al., 1997). Around the same time, human iNKT cells were also shown to be able to be
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stimulated with KRN7000 (Spada et al., 1998). These observations show that αGalCer is
a potent CD1d ligand.
Since the initial description of αGalCer as a CD1d ligand, there have been
numerous reports describing CD1d ligands that activate iNKT cells. Several groups
reported simultaneously the discovery of CD1d ligands from Sphingomonas paucimobilis
(Mattner et al., 2005; Sriram et al., 2005; Wu et al., 2005). These cell wall ligands were
structurally similar to αGalCer in that these glycosphingolipids (GSL) contain alphaoriented sugars attached to the lipid backbone (Sriram et al., 2005). Other agonists
include the galactosyl diacylglycerol BbGL-II from Borellia burgdorferi (Tupin et al.,
2008). Stimulation of iNKT cells with this antigen improved joint inflammation and
reduced spirochete load in BALB/c mice (Tupin et al., 2008). The initial endogenous
CD1d glycolipid discovered was isoglobotrihexosylceramide (iGb3), which has been
shown to activate both mouse and human iNKT cells (Mattner et al., 2005; Sanderson et
al., 2013; Zhou et al., 2004). Other iNKT cell agonists include glycosylceramides and
lysophospholipids (lysophosphatidylcholine), both of which have been reported as
endogenous human iNKT self-ligands (Fox et al., 2009; Kain et al., 2015).
While treatment with αGalCer induces iNKT cells to produce both IFNγ and IL4, the synthesized iNKT cell agonist OCH has been shown to elicit a Th2 bias, priming
iNKT cells to make IL-4 (Oki et al., 2004). OCH is a molecule like αGalCer except with
a shorter sphingosine moiety (Velmourougane et al., 2009). In an EAE model, OCH was
shown to protect C57BL/6 mice stimulated with OCH and sensitized with MOG peptide
from disease whereas αGalCer did not (Miyamoto et al., 2001). In contrast to OCH,
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modification of a sphinganine backbone instead of sphingosine, and the addition of a
hydrocinnamoyl ester to the galactose sugar (Chennamadhavuni et al., 2018) resulted in a
compound (AH10-7) capable of inducing higher amounts of IFNγ from both mouse and
human iNKT cells. This agonist aided in protection from B16 melanoma metastasis in
both mouse and humanized CD1d mouse models (Chennamadhavuni et al., 2018).
Although iNKT cells are resistant to polarization in the traditional sense
(Matsuda et al., 2003), modification of CD1d agonists can elicit differential cytokine
responses from both mouse and human iNKT cells. This is an active area of investigation
as new compounds are being synthesized to specifically activate iNKT cell responses to
combat solid tumors (Hung et al., 2017).

1.5 NKT cell Cytokines and Immunity
Cytokine production is one of the major mechanisms through which iNKT cells
mediate their action (Figure 1-2). Like T helper cell subsets, NKT cell IFNγ is important
for preventing B16 melanoma tumor burden (Smyth et al., 2002), and is being
investigated for treatments for other solid tumors (Ma et al., 2018; Tagawa et al., 2013).
Interferon-gamma from iNKT cells is also critical for mediating protection in several
disparate models of infectious disease (Behar et al., 1999; Gonzalez-Aseguinolaza et al.,
2002; Li et al., 2007; Nakamatsu et al., 2007). For example, IFNγ from iNKT cells was
shown to protect BALB/c mice from Pseudomonas by increasing the engulfment of
bacteria from alveolar macrophages (Nieuwenhuis et al., 2002).
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Interleukin-4 from iNKT cells is also critical in many different disease models,
especially in the regulation of airway diseases such as allergy, asthma, and
transplantation (Akbari O, 2003; Chuang et al., 2018; Meyer EH, 2006). In a model of
organ transplantation tolerance, iNKT cell IL-4 induced T-reg production of IL-10,
(Hongo et al., 2012) aiding in organ tolerance. Additionally, the iNKT IL-4 production
was associated with activation of myeloid derived suppressor cells (MDSCs) which was
important for host acceptance of heart and bone marrow transplants (Hongo et al., 2014).
Third, IL-17 producing iNKT cells are important for inhibiting growth of ocular
Staphylococcus aureus in C57BL/6 mice (St Leger et al., 2018). Another study showed
that lung iNKT cells produced IL-17 and IFNγ after activation by respiratory DC’s. This
cytokine production subsequently lead to the recruitment of dendritic cells and
neutrophils to the lung after Streptococcus pneumonia infection, aiding in increased
clearance of the bacteria as compared to dendritic cell depleted controls (Ivanov et al.,
2012).
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FIGURE 1-2: Cytokine Production from NKT cells
Upon activation with a glycolipid agonist, NKT cells produce a myriad of cytokines
including type 1, type 2, IL-17, and IL-10. These cytokines are important for mediating a
cascade of immune cell activation, priming and recruiting other cells of the innate and
adaptive immune response to combat infection.

iNKT cells in the germinal center, also termed NKT follicular helper (NKTfh),
produce IL-21. IL-21 is known to have many effects on immune cells including
activation of macrophages, NK cells, conventional T cells and iNKT cells (Skak et al.,
2008). The IL-21 produced by human iNKT cells is crucial for B cell production of IgG
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and IgA (Wu et al., 2015). IL-21 from iNKT cells also provides a feedback loop inducing
further activation of iNKT cells, NK cells, T cells, and B cells (Coquet et al., 2007).
These regulatory mechanisms were especially important for controlling Mycobacterium
tuberculosis infection (Paidipally et al., 2018). Patients undergoing recombinant IL-21
therapy for the treatment of malignant melanoma showed increases in the frequency of
iNKT cells during therapy (Coquet et al., 2013). Taken together, IL-21 from iNKT cells
results in activation of other immune cells while further activating iNKT cells.
The regulatory cytokine IL-10 is produced by iNKT cells in disease specific
contexts as well. In a model of cardiac ischaemia-reperfusion, αGalCer treated C57BL/6
mice showed reduced blood pressure and increased prevalence of heart remodeling due to
an infiltration of IL-10 producing iNKT cells to the heart (Wang et al., 2018). IL-10
producing iNKT cells are also important in regulation of adipose tissue (Sag et al., 2014).
iNKT cells are abundant in fat tissue, and over 25% of the iNKT cells in the adipose
tissue produce IL-10 (Exley et al., 2014). Interestingly, Jα18-/- and CD1d-/- mice, which
lack iNKT cells, gained more weight and had increased serum glucose as compared to
wild-type controls. These data implicate IL-10 producing adipose tissue iNKT cells as
being critically important for the regulation of metabolic disease (Lynch et al., 2012).
Therefore, the cytokines produced by iNKT cells are important in regulating the
immune response to numerous different disease models.
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1.6 Compartmentalizing NKT cells: iNKT cell subsets
Recently, new subsets of iNKT cells have been described that possess preformed
transcripts of IFNγ (NKT1), IL-4 (NKT2), IL-17 (NKT17), IL-10 (NKTreg), and IL-21
(NKTfh) (Chang et al., 2011; Lee et al., 2013; Lee et al., 2016; Sag et al., 2014). These
are functionally similar to their conventional T helper cousins in that they express
primarily IFNγ, IL-4, IL-17, IL-10, and IL-4 and IL-21 respectively. Each of these
subsets express specific transcription factors that enable their identification. All iNKT
cells express the master transcription factor promyelocytic leukaemia zinc finger (PLZF)
to various degrees as well as specific transcription factors that regulate cytokine
production (Savage et al., 2008). NKT1 cells are PLZFlowTbethigh, NKT2 cells
PLZFhighGATA3high, and NKT17 cells are PLZFintRORγthigh (Lee et al., 2013). NKTfh
cells express Bcl-6 and markers on their surface similar to conventional Tfh cells
including the chemokine CXCR5 and the inhibitory markers PD-1 and ICOS (Chang et
al., 2011). NKT10 cells are still an enigma in the field (Sag et al., 2014). These cells do
not express PLZF, but E4 promoter-binding protein 4 (E4BP4) which has been
implicated in IL-10 and IL-13 production in CD4 T cells (Motomura et al., 2011).
Some reports suggest that iNKT10 cells are indeed a distinct subset, while others suggest
that earlier subsets may differentiate into iNKT10 cells after stimulation and proliferation
(Cameron and Godfrey, 2018). Recently, an additional subset of iNKT2 cells that do not
produce IL-4 but express Tbet in addition to GATA3 has been identified (Engel et al.,
2016). It has been suggested that this is a precursor population to the IL-4 producing
iNKT2 cells (Crosby and Kronenberg, 2018).
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FIGURE 1-3: NKT cell Subset Characteristics
NKT cell subsets are comprised of NKT1, NKT2, and NKT17 cells, each expressing a
different transcription factor repertoire as well as surface marker expression patterns.
Distinct subsets are localized to specific tissues and primarily make cytokines such as IFNγ,
IL-4, and IL-17 respectively.

iNKT cell subsets are contributors to iNKT cell mediated tissue immunity. Each
organ appears to have a specific iNKT cell milieu with great diversity in the percentages
of subsets (Lee et al., 2015). For example, NKT1 cells are highly represented in the liver
and gut, which receive microbial products from portal circulation. NKT2 cells are
enriched in the lung and mesenteric lymph node, and NKT17 cells are highly enriched in
the lung and peripheral lymph nodes. Not only do iNKT cell subset frequencies vary
among different tissues, but the anatomical location of NKT cell subsets vary within
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tissues (Lee et al., 2015). This location specificity is presumably to position iNKT cells at
strategic locations for cross-talk with other immune cells and for specific activation
requirements. In the spleen, NKT1 cells are thought to reside in the red pulp, while NKT2
cells are located within the T cell zone (Lee et al., 2015). In the lung, NKT17 cells are
located within the interstitial tissue, whereas NKT1 and NKT2 cells are primarily in the
vasculature (Scanlon et al., 2011; Thanabalasuriar et al., 2016). NKT10 cells are
primarily found in the gut while (Sag et al., 2014) liver NKT1 cells patrol the liver
sinusoids (Lee et al., 2010). The anatomical locations of iNKT cells appear to have
consequences for differences in iNKT cell activation. For example, NKT1 cells in the
spleen and liver were activated after intravenous administration of αGalCer whereas only
NKT2 and NKT17 cells in the mediastinal lymph node were activated after oral gavage
(Lee et al., 2015). These data suggest that location within the tissue and route of
activation are all important for the cytokine milieu produced by iNKT cells.
The mechanisms underlying NKT cell subset development in the thymus remain
unclear. There are two models to explain how iNKT cell subset development fits into
classical models of iNKT cell development. Classic NKT cell staging, discussed in
section 1.2, postulates that iNKT cells follow a linear stage model progressing from Stage
0 (CD44negNK1.1neg), to Stage 3 (CD44posNK1.1pos) passing through each stage
sequentially (Benlagha et al., 2005). Upon the identification of iNKT subsets however, it
was found that these developmental stages were characterized by specific NKT cell
subsets (Lee et al., 2013). NKT1 cells are the most mature Stage 3 cells, Stage 2 are
NKT2, and Stage 1 are both NKT2 and NKT17 cells. The second model suggests that
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iNKT cells do not follow a sequential model of development and instead suggests that
each iNKT cell subset may have a separate precursor cell (Chen et al., 2017; Lee et al.,
2013). Evidence for a precursor population comes from thymic transcriptome analyses
that show non-traditional iNKT2 cells can express Tbet, indicating a distinct cell type
other than those able to express IL-4 (Engel et al., 2016; Georgiev et al., 2016). To date,
the mechanisms that regulate each of the iNKT cell subsets and how they are
developmentally controlled in both the thymus and periphery remain undetermined.
While definitive iNKT cell subsets based on transcription factors in the human
have not been identified, there are subsets of human iNKT cells that have propensities for
different cytokines. The human subsets consist of CD4+CD8neg, CD4negCD8+, DN and DP
(O'Reilly et al., 2011). After in vitro stimulation, human iNKT cell subsets produce
similar levels of IFNγ and TNFα, but CD4+ iNKT cells specifically make higher levels of
IL-4 (Montoya et al., 2007). The CD8+ and DN human iNKT cells are also thought to be
more cytotoxic (Baker et al., 2001). The CD4+ human iNKT cells have been shown to
provide an important role in antibody production by inducing B cell proliferation (Zeng
et al., 2013). Therefore, iNKT cell subsets in both mouse and human contribute to tissue
specific immune responses.
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1.7 Genetic regulation of NKT cells
Invariant natural killer T cells exhibit immense strain specific diversity in
number and function in mice (Chen et al., 2012; Rymarchyk et al., 2008). A comparison
of iNKT cell numbers in common inbred strains of mice revealed a 50% difference in the
percentage of iNKT cells in the liver (Rymarchyk et al., 2008). C57BL/6 mice, the most
commonly used inbred mouse strain, has an above average number of iNKT cells,
whereas BALB/c and C3H/HeJ mice harbor half as many (Hammond et al., 2001).
Additionally, wild-derived inbred strains of mice such as Cast/EiJ and PWD/PhJ have
barely detectable numbers of iNKT cells (Chen et al., 2012). Invariant NKT cell subsets
also show variation in number and localization among different inbred strains of mice
(Lee et al., 2015). C57BL/6 mice have the most NKT1 cells in all organs while BALB/c
mice are enriched in NKT2, and NOD in NKT17. These analyses indicate that the host
genetic background is important for the development of iNKT cells.
Strain dependent differences in NKT cell number are associated with strain
dependent variation in pathogen clearance. For example, infection with Borrelia
burgdorferi manifests as joint inflammation in CD1d-/- animals on a BALB/c background
(Tupin et al., 2008) but myocarditis on a C57BL/6 background (Olson et al., 2009). Data
from the Boyson lab show that the magnitude of lung iNKT cell cytokine responses in
BALB/c mice was higher than the responses of C57BL/6 after stimulation with both
αGalCer and anti-CD3 (Benoit et al., 2015). These data indicate that strain dependent
variation affects how iNKT cells respond to infection.
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Numerous groups have been working to identify genetic elements that regulate
iNKT cell number and function. Early work showed that iNKT cell number was
drastically diminished in the autoimmune prone non-obese diabetic (NOD) mouse model.
It was also shown that the number of iNKT cells in type 1 diabetic and SLE patients were
also diminished (Beristain-Covarrubias et al., 2015; Cho et al., 2011). Upon further
investigation to the cause of reduced iNKT cell number in the NOD mouse, the Nkt1
locus located on chromosome 1 was identified (Rocha-Campos et al., 2006). Numerous
congenic mice on the NOD and C57BL/6 background were generated, identifying smaller
regions of NOD alleles that could control NKT cell number and function (Esteban et al.,
2003; Jordan et al., 2004; Jordan et al., 2011; Jordan et al., 2007a). Importantly, a
congenic line in which the NOD Nkt1 locus was replaced with C57BL/6 alleles showed
no role in the disease susceptibility of type-1 diabetes, indicating that the susceptibility to
autoimmune disease in the NOD mouse may be due to several different genetic loci
(Rocha-Campos et al., 2006).
Numerous other studies have shown other genetic loci that control iNKT cell
number (Wesley et al., 2007; Zhang et al., 2003). One of the most interesting and studied
genetic regions, Sle1b on chromosome 1, was identified as a susceptibility locus for SLE
in New Zealand White (NZW) mice (Morel et al., 2001). This locus was associated with
increased auto-antibody production as well as germinal center formation. When the Sle1b
locus was introgressed onto the B6 background, only the mice harboring the NZW alleles
at the Sle1b locus (B6.Sle1b) exhibited signs of increased autoimmunity indicating that a
genetic determinant within this region provided susceptibility to lupus (Sobel et al.,
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2002). This locus contained several hundred immunologically relevant genes, including
the signaling lymphocyte activation markers (Slam genes) which had been associated
with lupus susceptibility in GWAS studies (Cunninghame Graham et al., 2008;
Wandstrat et al., 2004). Similar decreases in iNKT cell numbers were shown when
129X1/SvJ alleles were introgressed onto the C57BL/6 background from chr1: 171.24176.09Mbp (Ensemble build m38.p6). B6.129 congenic mice exhibited reduced numbers
of iNKT cells in the liver as well as reduced iNKT cell cytokine production upon
activation (Aktan et al., 2010), indicating that a gene or genes controlling iNKT cell
number was within this region on chromosome 1.
The same region was subsequently investigated for control of iNKT cell subset
numbers. A 6.0Mbp locus on chr1:171-177Mbp derived from NZB mice was
introgressed onto the C57BL/6 background. Importantly, this locus overlapped
extensively with the previous Nkt1, Sle1b, and B6.129 congenic loci and contained the
Slam genes. This locus also appeared to control iNKT cell subset development. B6.NZB
congenic mice exhibited increased numbers of NKT1 and NKT2 cells as compared to
C57BL/6 controls (Baglaenko et al., 2017). While each of the genetic loci reported used
different strains of mice, the data clearly demonstrated that a gene or multiple genes on
chromosome 1 from 171-177Mbp affected iNKT cell development.
These large genetic loci however, contained over 80 immunologically relevant
genes, including the Slam genes, which were suspected candidates in controlling iNKT
cell number and function (Aktan et al., 2010; Wandstrat et al., 2004). The Boyson lab
therefore followed up on these studies and generated numerous congenic mice with
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varied 129X1/SvJ congenic intervals and assessed iNKT cell responses. Identification of
the candidate gene or genes regulating iNKT cell number and function was a major goal
of this dissertation in Chapter 4.

1.8 SLAM receptors: fine-tuning the immune system
Signaling lymphocyte activation markers (SLAMs) are cell surface receptors
expressed on all hematopoietic cells (Wu and Veillette, 2016) (Figure 1-4). These
receptors are part of the CD2 family of cell surface receptors sharing similar Ig domain
folds on their cell surface. The SLAM family receptors, except for SLAMf2 which binds
SLAMf4, bind homotypically to self-receptors on opposite cells. Crosslinking of SLAM
family receptors results in signaling leading to numerous functions on immune cells such
as cell-cell adhesion, activation, cytokine production, cell proliferation, cell death, and
cytotoxicity (Cannons et al., 2011). Interestingly, the SLAM family receptors are
heterogeneously expressed on different cell types. These patterns of expression could
possibly aid in lending specificity of signaling to cell interactions, be it co-stimulation
leading to cytokine production from T cells (Howie et al., 2002), adhesion of T cells to B
cells or antigen presenting cells (Zhao et al., 2012), antibody production from B cells
(Cannons et al., 2006), or cytotoxicity from NK cells (Dong et al., 2012; Meinke and
Watzl, 2013). SLAMf1 has been shown to function as a costimulatory receptor on T
cells, SLAMf6 signaling aids in B cell help for proliferation and antibody production,
while SLAMf4 mediates both inhibitory and activating signals for NK cell cytotoxicity
(Chlewicki et al., 2008; Howie et al., 2002; Radomir et al., 2017).
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FIGURE 1-4: SLAM Family Receptors
SLAM family receptors are a family of nine cell surface expressed molecular switches that
signal via immuno-tyrosine switch motifs within the cytoplasmic domain. These receptors,
with the exception of SLAMf2-SLAMf4, primarily bind homotypically to each other on
neighboring cells. This crosslinking allows for the phosphorylation of traditional tyrosine
motifs or ITSMs via the adaptor molecule SLAM adaptor protein (SAP), or other adaptor
moleculars such as the phosphatase SHP-1. Each SLAM family receptor has a different
repertoire of tyrosine phosphorylation sites and ITSM configurations.

Deletion of SLAM family receptor signaling by mutating the SLAM adaptor
protein (SAP) gene has detrimental effects on multiple immune cell functions (Cannons
et al., 2006; Nichols et al., 2005a; Nichols et al., 2005b; Rivat et al., 2013). SAP is
located on the X-chromosome, and is the mutated gene in X-linked lymphoproliferative
disorder (XLP) (Coffey et al., 1998; Nichols et al., 1998; Sayos et al., 1998). Young boys
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who acquire this deletion are unable to control Epstein Bar Virus and succumb to the
virus at a young age. These patients have increased white blood cells due to defects in
activation induced cell death. Conventional CD8 T cells and NK cells fail to kill virally
infected cells. These patients also have defects in antibody production and formation of B
cell blasts (Purtilo et al., 1975). XLP patients fail to develop iNKT cells, indicating that
SLAM/SAP signaling is required for the development of this subset of αβ T cells
(Pasquier et al., 2005). Therefore, SLAM family receptor signaling is necessary for the
proper functioning and development of immune cells.
SLAM family receptors 1-7, except for SLAMf2, contain immuno-tyrosine
switch motifs (ITSM) on their cytoplasmic tails (Shlapatska et al., 2001) (Figure 1-4).
ITSMs are different from other immune regulatory motifs such as the immune-tyrosine
activation motif (ITAM) and immune-tyrosine inhibitory motif (ITIM). Whereas the
activation and inhibitory motifs can only bind adaptor molecules that result in activation
or inhibition respectively, the ITSM regulatory tails allow for activating or inhibitory
signaling based on the repertoire of adaptor molecules expressed in the cell. The SLAM
adaptor molecule, slam adaptor protein (SAP), can bind to the immuno-tyrosine switch
motifs, which leads primarily to activation phenotypes (Shlapatska et al., 2001). If SAP is
not bound, the inhibitory phosphatase, src-homology region 2 domain containing
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FIGURE 1-5: Signaling Through SLAM Receptors
Schematic of SLAM family receptor signaling via the adaptor molecules SAP or SHP-1.
SAP is thought to provide activation signals via the recruitment of Fyn kinase. Binding of
SAP to an ITSM blocks SHP-1 from binding. Alternatively, in the absence of SAP binding,
SHP-1 can bind to the SLAM family receptor ITSM, generally resulting in inhibitory
signaling.

phosphatase 1 (SHP-1), can also bind (Kageyama et al., 2012) (Figure 1-5). Which
adaptors are bound to the SLAM family receptors in different cells remains controversial.
Initial reports observed that SAP was constitutively bound to SLAM family receptors on
T cells, while SHP-1 could displace SAP (Dong et al., 2009; Sayos et al., 1998; Tangye
et al., 2000), resulting in a decreased activation signal or possibly even an inhibitory
signal. An alternative model states that SHP-1 may be constitutively bound and SAP
outcompetes SHP-1 for binding to the same ITSM, thereby decreasing the inhibitory
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signal (Wilson et al., 2014). Other reports speculate, but have not unequivocally shown,
that SAP can be bound to one ITSM and SHP-1 to a second on the same SLAM family
receptor (Kageyama et al., 2012). Therefore, SLAM family receptor signaling on
different immune cells can have both activating and inhibitory phenotypes.
One of the most striking examples of activation and inhibitory signaling
phenotypes is shown by analysis of SLAMf4 expression on NK cell lines (Chlewicki et
al., 2008). In vitro, high expression of SLAMf4 resulted in inhibition of cytokine
production while a lower level of SLAMf4 correlated with an activation phenotype and
increased cytokine production of NK cells. The inhibitory and activation levels were
dependent not only on SLAMf4 expression, but on ligand crosslinking (i.e. with
SLAMf2), as well as the expression level of SAP. Interestingly, lower levels of SAP were
associated with inhibition while higher levels showed activation, indicating that the ratio
of adaptor molecule binding to ITSMs on the SLAM family receptor contribute to how
the receptor mediates function (Chlewicki et al., 2008).
Furthermore, analysis of SLAMf4 and SLAMf6 in SAP-/- mice show that these
receptors can have both inhibitory and activating functions in vivo. In the presence of
SAP, SLAMf4 and SLAMf6 were required for activation signals to mediate adhesion of
T cells to target cells at the immunological synapse (Zhao et al., 2012). In SAP deficient
mice, SHP-1 was recruited to the ITSM, and cell-cell contact time was diminished
resulting in decreased cell killing and activation of B cells. Thus, SLAMf4 and SLAMf6
can have an activating function in the presence of SAP, but inhibitory functions without
SAP (Zhao et al., 2012).
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SLAM family receptor signaling is critical for the development of certain
lineages of innate-like T cells. There are SLAM/SAP dependent γδ T cells, innate-like
CD8+ T cells, and iNKT cells (De Calisto et al., 2014; Griewank et al., 2007; Kreslavsky
et al., 2009). SAP deficient mice lack a specific subset of “NKT-like” gamma-delta T
cells that express a characteristic Vγ1.1Vδ6.3 TCR (Kreslavsky et al., 2009). The field
still has yet to determine which SLAM family receptors in particular are required for
development of this cell type. SLAMf5 deficient mice have an increase in CD8+ innate T
cells as compared to wild-type mice, implicating SLAMf5 as a regulator of innate CD8+
T cell development (De Calisto et al., 2014). SLAMf1, SLAMf6, and recently SLAMf3
have all been implicated in the development of iNKT cells, which will be discussed more
in the next section (Griewank et al., 2007; Sintes et al., 2013). MAIT cells do not appear
to be dependent on SLAM/SAP for development (Garner et al., 2018). To date, SLAM
family receptors have not been shown as crucial for the development of conventional T
cells, indicating that innate like T cells are more dependent on SLAM family receptor
signaling than conventional T cells.

1.8.1. SLAM family receptor 6 (SLAMf6, Ly108, NTB-A)
SLAM family member receptor 6 (SLAMf6) is thought to have diverse effector
functions on multiple immune cells. This receptor has been shown to have costimulatory
functions on naive CD4 T cells and NK cells, and inhibitory functions on re-stimulated
conventional T cells as well as iNKT cells. Initial investigations into the role of SLAMf6
on conventional CD4 T cells showed that SLAMf6 deficient T cells produced less IL-4
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after Leishmania mexicana challenge (Howie et al., 2005),

as well as reduced

phagocytosis of Salmonella typhimurium by neutrophils, showing that SLAMf6 could
control functions of both innate and adaptive immune responses.
Next, SLAMf6, also termed Ly108, and “NK, T and B cell antigen (NTB-A)” in
the human, was identified as a potential susceptibility gene for autoimmunity, especially
in systemic lupus erythematosus (SLE) (Wandstrat et al., 2004). The first identification of
SLAMf6 as having a role in autoimmunity was due to an increase in the expression of
SLAMf6 on autoimmune prone (B6.Sle1b) mouse T cells as compared to C57BL/6 mice
(Wandstrat et al., 2004). Numerous reports showed that SLAMf6 enhanced signaling in
CD4 T cells (Chatterjee et al., 2011), regulated autoantibody production (Keszei et al.,
2011), and was important with SAP for B cell help and germinal center formation (Wong
et al., 2015). SLAMf6 and SLAMf3 expression were increased on CD4 T cells of SLE
patients, indicating that SLAMf6 functioned, in part, to aid in promoting SLE aberrant T
cell signaling (Chatterjee et al., 2012).
Recently, SLAMf6 has been shown to have roles as a negative regulator in
humoral immunity. Deletion of SLAMf6, SLAMf5, and SLAMf1 resulted in higher
antibody responses, T follicular helper cell formation, and germinal center formation.
Additionally crosslinking SLAMf6 with an anti-SLAMf6 antibody reduced Tfh
formation, and antibody responses, indicating that SLAMf6 also acts as a negative
regulator in modulating antibody responses (Wang et al., 2015).
SLAMf6 is also thought to play an active role in binding bacteria such as
Citrobacter rodentium, E coli, and Salmonella (van Driel et al., 2015). Engagement of
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SLAMf6 with the OmpF and OmpC proteins on E. coli allowed SLAMf6 to transmit
signaling to activate neutrophils and phagocytic cells. SLAMf6 -/-Rag-/- mice were
protected from C. rodentium mediated colitis due to decreased inflammatory cell
localization to the gut decreasing the pathology from inflammation in this organ (van
Driel et al., 2015).
How is it that SLAMf6 could have a myriad of roles in both innate and adaptive
immune responses? The answer, in part, is due to the biology of SLAM family
receptors themselves. Since SLAM family receptors have ITSM motifs and can bind
multiple signaling molecules, as discussed earlier, SLAM receptors can change
signaling dependent on expression level and the strength of the signal received. Indeed,
SLAMf6 has been shown to act as “immune modulatory switch” providing activation
of T cells in the presence of SAP and inhibition of NKT cell development in SAP
deficient mice (Kageyama et al., 2012). Chapters 2 and 3 explore how SLAMf6 can
have multiple functions on the same immune cell type.

1.9 Slam gene polymorphisms
There are 9 SLAM family receptors within the Slam gene family, each of which
are termed SLAMf1-SLAMf9 (Cannons et al., 2011). Slams 1-7 are located within a
0.410Mbp region on chromosome 1. Slams 8 and 9 are located another 0.6Mbp telomeric
to the main Slam locus located at Chr1:171.55-171.96 (Ensembl Gene Browser, Build 93
GRCm38.p6). These genes and gene arrangement are conserved in both the mouse and
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human (Engel et al., 2003), indicating an evolutionary need to constrain these genes
(Limaye et al., 2008).
The Slam genes are found in 3 distinct haplotypes in inbred mouse strains, with
C57BL/6 harboring one haplotype, while NZW/B, BALB/c, and 129X1/SvJ harbor a
second. The third haplotype is only found in wild-derived inbred strains of mice such as
CAST/EiJ and PWD. Each of these haplotypes show variability in SLAM family receptor
gene expression, copy number, or isoform expression. For example, Slamf4 has 4
pseudogenes duplicated in mice that carry haplotype 2 alleles while C57BL/6 mice,
which harbor haplotype 1 alleles, express an inhibitory isoform of the SLAMf6 protein.
Slam polymorphisms have been shown to affect iNKT number and function
(Aktan et al., 2010; Esteban et al., 2003; Jordan et al., 2004; Jordan et al., 2007b).
Previous reports had indicated immense strain dependent variability in the number of
iNKT cells in different inbred strains of mice, raising questions about which genes
controlled the development of iNKT cells in these strains. The regions first identified as
iNKT cell control genes, Nkt1 and Sle1b, both contained Slam gene polymorphisms in
addition to many other immunologically relevant genes (Jordan et al., 2007a; Morel et al.,
2001). A major goal of the Boyson lab has been to refine these regions to identify the
gene or genes that control iNKT cell number and function.
Slam polymorphisms are also important for infection models. Boyson and Huber
showed that mice harboring the autoimmune prone Slam haplotype 2 promoted NKT cell
activation after coxsackie-B3 infection resulting in liver pathology. Slam haplotype 1
animals, or C57BL/6, showed more gamma-delta T cell responses, leading to induction
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of myocarditis (Huber et al., 2013). In addition, BALB/c mice, which harbor Slam
haplotype 2 alleles were more dependent on iNKT cells for the clearance of
Pseudomonas from the lung than C57BL/6 mice (Benoit et al., 2015). These infection
models describe how Slam polymorphisms may control iNKT cell responses to infection.

1.10 SLAM receptor regulation of NKT cells
iNKT cells are dependent on SLAM and SAP signaling in the thymus for
development. Using elegant chimeric models, Griewank et al. showed that SLAMf1 and
SLAMf6 with the adaptor molecule SAP are required on double positive thymocytes for
iNKT cell selection (Griewank et al., 2007). Subsequent reports have now shown that
SLAMf3 is a negative regulator of iNKT cell development (Sintes et al., 2013). Analysis
of numerous SLAM family receptor single knockouts, as well as multiple SLAM family
receptor knockouts have shown skewed ratios of NKT1, NKT2, and NKT17 subsets as
compared to wild-type parental controls, indicating that multiple SLAM family receptor
signals play a role in iNKT cell subset development (Baglaenko et al., 2017; Graham et
al., 2006; Huang et al., 2016).
The role of SLAM family receptor signaling on iNKT cell subset development is
exemplified by the fact that SAP appears to contribute to IL-4 and NKT2 development
(Michel et al., 2016). SAP deficient mice crossed with transgenic Vα14 mice, which
allow for iNKT cell production even though these mice lack SAP, showed an increase in
the level of iNKT17 cells along with a decrease in NKT2 cells (Michel et al., 2016).
While these results are indicative of a role for SLAM/SAP signaling in iNKT cell subset
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development, the transgenic mouse model used may have confounded results. Initial
reports show that this mouse has an increase in NK1.1 NKT cells compared to parental
controls, indicating that the Vα14 transgenic has developmental differences in iNKT cell
subsets (Bendelac et al., 1996). Additional investigation into the role of SLAM/SAP
signaling on the development of iNKT cell subsets is ongoing by us and others.
Several studies have shown that SLAMf6 specifically is a regulator of iNKT cell
development. SLAMf6 is required for the induction of the iNKT cell master transcription
factor promyelocytic leukaemia zinc finger (PLZF). Treatment of pre-selected
thymocytes with anti-SLAMf6 and anti-CD3 induced higher expression of PLZF than
treatment with anti-CD3 alone (Dutta et al., 2013). Another report showed that SLAMf6
was a negative regulator of NKT cell development. SLAMf6 deficient mice show a 50%
reduction in NKT cells, and SAP deficient mice lack all NKT cells completely
(Kageyama et al., 2012; Nichols et al., 2005a). Interestingly, a partial restoration of NKT
cells was observed in SLAMf6-/-SAP-/- mice, suggesting that SLAMf6 acts as negative
regulator in SAP-/- animals (Kageyama et al., 2012). Additionally, crosslinking of
SLAMf6 on APCs and iNKT cells are critical for the cytokine production of iNKT cells
in the mouse and human, indicating that SLAMf6 can also act as an activation receptor
upon homotypic binding (Baglaenko et al., 2017). SLAMf6 has been shown to be
involved in the induction of PLZF, yet the deletion of SLAMf6 by itself is not sufficient
to completely block iNKT cell development, indicating that other SLAM family receptors
also aid in iNKT cell development. These studies did not address function of SLAMf6 on
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iNKT cell subsets. These observations raise questions about the mechanisms of SLAMf6
function on peripheral iNKT cell subsets, which are discussed in Chapters 2 and 3.
Multiple SLAM family receptors can provide both positive and negative signaling
in iNKT cell development. As noted above, deletion of SLAMf6 decreases the number of
iNKT cells in the thymus by 50% (Dutta and Schwartzberg, 2012). A SLAMf1, SLAMf5,
SLAMf6 triple knockout, however, decreases NKT development by over 80% (Huang et
al., 2016). This report indicates that SLAMf1 and SLAMf5 may provide positive
signaling for NKT cell development while SLAMf6 provides an inhibitory signal.
Additional reports observed that total SLAM family receptor knockouts had a less severe
decrease in iNKT cells as compared to SAP-/- mice, indicating that all SLAM family
receptors can negatively regulate iNKT cell development when SAP is absent (Chen et
al., 2017). Interestingly, SAP deficiency induced after iNKT cell development resulted in
a decrease in peripheral iNKT cell mediated cytotoxicity, but not cytokine production,
indicating that the major role for SAP on iNKT cells could possibly be only in
development (Das et al., 2013). These phenotypes highlight the importance of
SLAM/SAP signaling in iNKT cell development.

1.11 The role of SLAM family receptors on iNKT cell proliferation

iNKT cells are thought to have an activated phenotype immediately upon
emigration from the thymus (Kumar et al., 2017). This primed state not only leads to
quick secretion of cytokines, but also rapid proliferation, and as a result, rapid cell death.
The balance of this proliferation and cell death has been the focus of numerous studies
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since iNKT cells were discovered, but these studies have been controversial (Eberl and
MacDonald, 1998) (Crowe et al., 2003; Subleski et al., 2011). One of the first reports on
this topic suggested that liver iNKT cells rapidly undergo apoptosis after activation with
in vivo anti-CD3ɛ (Eberl and MacDonald, 1998). Numerous reports further showed that
this cell death was due to Fas/FasL interactions since FasL is highly expressed on iNKT
cells (Leite-de-Moraes et al., 2000). Subsequently, it was shown that splenic NKT cells
down regulate their TCR in response to a strong stimulus, making these cells impossible
to detect using CD1d/αGalCer loaded tetramer (Crowe et al., 2003). Recently, both
models were found to occur in that NKT cells in the liver undergo activation induced cell
death but iNKT cells in the spleen do not. Surprisingly, iNKT cells from both the spleen
and liver downregulated their TCR, but cells in the lymph node did not downregulate
their TCR or undergo cell death (Subleski et al., 2011). These data point to specific
subsets of iNKT cells being more susceptible to cell death than others. Indeed, recent data
has shown than NKT2 cells are much more proliferative than NKT1 cells (Cameron and
Godfrey, 2018). Further transcriptomic reports indicate that iNKT cell subsets have
different propensities and thresholds for activation and cell death (Engel et al., 2016;
Georgiev et al., 2016), the implications of which are only now being addressed.
Little is currently known about the role of SLAM family receptors in
homeostatic mechanisms of peripheral iNKT cells. Although SLAMf1 and SLAMf6 are
required for iNKT cell development (Griewank et al., 2007), it remains to be determined
whether SLAMf6-SLAMf6 interactions mediate proliferation or cell death in the
periphery. Yet, analysis of reactivation induced cell death shows that SLAMf6 may be
34

involved in regulating iNKT cell homeostasis. Signaling of SLAMf6 via the adaptor
molecule SHP-1 in XLP patients, who lack SAP, caused CD8 T cells to over proliferate
and prevented them from undergoing cell death (Snow et al., 2009). When SLAMf6 was
knocked-down, however, the resistance to cell death was reversed, and the majority of
CD8 T cells underwent apoptosis (Snow et al., 2009). Additionally, SLAMf6 and
SLAMf4 were shown to regulate CD8 T cell mediated cytotoxicity against B cells, which
is an important function for fighting EBV infection (Zhao et al., 2012).
In the past several years, the unique property of SLAMf6 to change the signaling
thresholds for cell death has been exploited in new immuno-therapeutics for leukemia
and metastatic melanoma (Eisenberg et al., 2018; Korver et al., 2007). SLAMf6 has been
shown to be highly expressed on B cells, with even greater expression on leukemic B
cells. Monoclonal antibodies that target SLAMf6 result in enhanced cell death against the
leukemic B cells, preventing the cancer from progressing (Korver et al., 2007). In
addition, soluble SLAMf6 has been shown to improve CD8 T cell cytotoxicity and
activation against melanoma tumors in a mouse model (Eisenberg et al., 2018). These
data suggest that SLAMf6 can modulate the cytotoxic and cell death thresholds of
lymphocytes, which have important implications in the treatment of cancer.
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1.12 Gaps in knowledge of NKT cell regulation

SLAM family receptors have been regulated as modulators of lymphocyte
function since 1993 (Garni-Wagner et al., 1993). Although there have been many studies
of SLAM family receptors on T cells and NK cells leading to identification of SLAM
family receptors mediating cell-cell contact at the immunological synapse, co-stimulation
of T and B cells, and inhibition of cytokine production, little is known about how SLAM
family receptors function on iNKT cells in the peripheral tissues. Most studies of SLAM
family receptors on iNKT cells are centered upon how these receptors mediate signals
during development, leading to broad knowledge of how iNKT cell development is
fundamentally different from that of conventional T cells. Other reports have investigated
cytokine production after thymic iNKT cell stimulation in vitro, but not on iNKT cells
from the spleen, lung and liver. Therefore, there is a gap in knowledge of how SLAM
family receptors are expressed and if these patterns mediate functionality of peripheral
iNKT cell subsets.
The recent discovery of iNKT cell subsets raises new questions about how the
SLAM family receptors are involved in development and function of these subsets. We
know that SLAMf1 and SLAMf6 with SAP are required for the development of all iNKT
cells (Griewank et al., 2007), but how these two proteins affect subset development has
not been addressed. Since C57BL/6 mice have mostly NKT1 cells (70% or higher in the
spleen) (Lee et al., 2015) (Boyson lab observations), differences in iNKT cell phenotypes
have not been discovered until NKT1 cells were separated from NKT2 and NKT17.
Additionally, a report of SLAMf6-deficiency on subsets of iNKT cells has not been
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performed. Therefore, a major goal of this dissertation was to assess SLAM family
receptor patterns of expression and how these patterns controlled NKT cell subset
development and peripheral function. A second goal was to analyze specific coexpression of SLAM family receptors on subsets of iNKT cells in both the C57BL/6 and
SLAMf6-/- mice, identifying specific roles for SLAMf6 on iNKT cell subsets.
Finally,

there

have

been

numerous

studies

implicating

Slam

gene

polymorphisms in the control of total iNKT cell number and function (Aktan et al., 2010;
Baglaenko et al., 2017). Whether these loci control all iNKT cell numbers or just certain
subsets still needs to be determined. Most of the susceptibility studies were performed on
mice with large congenic loci, containing numerous immunologically relevant genes.
There has not been a definitive study showing that the Slam genes were the regulators of
iNKT cell number and function. How to refine one of these loci and whether Slam genes
may be involved in the regulation of iNKT cell number and function is discussed in
Chapter 4.
Therefore, the major goals of this dissertation were first, to broadly analyze
SLAM family receptor expression on peripheral iNKT cells in the lung, liver, and spleen
and assess the functional implications of these patterns of expression. Second, to assess
the role of SLAMf6 signaling on the newly described iNKT cell subsets, and whether this
receptor can lead to multiple phenotypes across the iNKT cell lineage. Third, to address
whether Slam genes control iNKT cell number and function. These data, overall, provide
novel understanding of the mechanisms by which iNKT cells are modulated in secondary
organs, and provide context for how these cells contribute to host immunity.
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2.1. Abstract
Invariant natural killer T cells (iNKT) are crucial for mediating host immunity in
a tissue specific manner. When activated, these cells produce a myriad of cytokines
including IFNγ, IL-4, IL-10, and IL-17. Each of these cytokines is primarily produced by
specific iNKT cell subsets termed NKT1, NKT2, NKTreg, and NKT17, respectively. The
cell surface-expressed family of signaling lymphocyte activation markers (SLAM) have
been shown to play a role both in the development and function of iNKT cells, but a role
on specific iNKT cell subsets has not been shown. Here, we analyze SLAM family
receptor co-expression on iNKT cell subsets revealing tissue and strain dependent
differences in SLAM family receptor expression. These observations led us to
hypothesize that SLAM family receptors could fine-tune development and function of
iNKT cell subsets. Indeed, SLAMf6 was highly expressed on NKT2 and NKT17 subsets.
Deficiency of SLAMf6 resulted in decreased NKT2 and NKT17 cell numbers as well as
IL-4 and IL-17 production from sorted NKT2/NKT17 cells. Taken together, these data
show that SLAM receptor expression patterns define iNKT cell subsets, and that
SLAMf6 has a functional role in NKT2 and NKT17 subset specific development.
Additionally, this is the first report that SLAMf6 deficiency has a specific effect on
NKT17 IL-17 production and NKT2 IL-4 production, showing that SLAM family
receptor expression also mediates function of these iNKT cell subsets.
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2.2. Introduction
Invariant natural killer T cells are innate-like T cells that play a crucial role in the
host immune response (Behar and Porcelli, 2007; Godfrey and Rossjohn, 2011;
Gumperz and Brenner, 2001). These invariant cells recognize glycolipids bound by the
MHC class-1 like molecule CD1d (Kawano et al., 1997; Spada et al., 1998). When
activated by the prototypical agonist alpha-galactosylceramide (αGalCer), iNKT cells
make a host of inflammatory mediators such as IFN-γ, IL-4, TNFα, IL-17, and the antiinflammatory cytokine IL-10 (Coquet et al., 2008; Hameg et al., 2000; Yoshimoto and
Paul, 1994).
iNKT cell cytokines play critical roles in immune function and underlie the
critical role of iNKT cells in many disease models (Crosby and Kronenberg, 2018). For
example, IFN- produced by iNKT cells is critical for secondary activation of NK cells
and subsequent killing of metastatic tumors in a B16 melanoma model (Smyth et al.,
2002), and activation of macrophages by IFNγ-producing lung iNKT cells is crucial for
decreasing Pseudomonas bacterial burden in the lung (Nieuwenhuis et al., 2002).
Similarly, IL-17 from lung iNKT cells is associated with neutrophil recruitment
clearance of Streptococcus pneumoniae from the lung (Ivanov et al., 2012). Finally,
iNKT-derived IL-21 has been implicated in aiding clearance of Mycobacterium
tuberculosi (Wu et al., 2015), and iNKT-derived IL-10 has been shown to protect mice
from metabolic disease (Lynch et al., 2012).
Recently, several subsets of iNKT cells have been identified that preferentially
transcribe IFN-γ (NKT1), IL-4 (NKT2), and IL-17 (NKT17) cytokines, much like the T
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helper subsets of conventional T cells (Coquet et al., 2008; Hameg et al., 2000; Lee et al.,
2013). Invariant NKT cells that produce IL-21 (NKTfh) (Chang et al., 2011) and IL-10
(NKTreg) (Sag et al., 2014) have also been described. The iNKT cell subsets reside
preferentially in distinct peripheral tissues, with NKT1 cells homing to the liver, NKT2 in
the spleen, NKT17 in the lung and mesenteric lymph node, and NKTreg cells
preferentially homing to the gut and adipose tissue (Lee et al., 2015; Lynch et al., 2015).
Invariant NKT cell subsets are also highly mouse strain dependent in that C57BL/6 mice
possess more NKT1 cells than do BALB/c, while BALB/c possess increased numbers of
NKT2 cells. NKT17 cells are most prevalent in NOD mice (Lee et al., 2015). These
newly defined subsets could explain the heterogeneity in iNKT cell function and how
these cells can regulate the immune response in a tissue-dependent manner. However, the
mechanisms by which iNKT cell subsets develop and how they can regulate the immune
response are largely unknown.
The signaling lymphocyte activation markers (SLAMs) and the associated
signaling adapter protein SAP play critical roles in NKT cell development (Chen et al.,
2017; Griewank et al., 2007; Nichols et al., 2005a; Sintes et al., 2013). The nine SLAM
family receptors are widely expressed on all hematopoietic cells where they play critical
roles in signaling and in cell adhesion (Cannons et al., 2011). Specifically, homophilic
interactions among the SLAMf1 and SLAMf6 receptors expressed on thymocytes have
been demonstrated to be critical in iNKT cell development (Griewank et al., 2007;
Kageyama et al., 2012), while SLAMf3 has been demonstrated to be a negative regulator
of NKT cell development (Sintes et al., 2013).
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Importantly, SLAM family receptors have been implicated in the modulation of
cytokine production in multiple leukocyte subsets. SLAMf6 was demonstrated to be
critical in CD4+ T cell IL-4 production (Howie et al., 2005). SLAMf3 and SLAMf6
engagement has been linked to IL-17A production in human lupus patients (Chatterjee et
al., 2012) and SLAMf1 leads to increased TNFα and IL-1β after mycobacteria infection
(Aversa et al., 1997; Jordan et al., 2007b; Song et al., 2015). However, the extent to
which SLAM receptors modulate iNKT cell cytokine production is far less clear. While
deletion of multiple SLAM receptors does have a significant impact on iNKT cell
cytokine production (Chen et al., 2017; Huang et al., 2016), the pleiotropic nature of the
Slam gene family has made it difficult to assign specific functional roles for individual
SLAM family receptors to iNKT cells.
Here, we explored the levels of SLAMf1, SLAMf4, and SLAMf6 co-expression
on αβ T cells and report the presence of a distinct profile of SLAM family receptor
expression on iNKT cells. These SLAM family receptor expression profiles were organ
specific and strain-dependent. Importantly, when we extended our analysis to the subsets
of iNKT cells, we found that the SLAM family receptor co-expression of SLAMf1,
SLAMf4, and SLAMf6 allowed us to delineate specific iNKT cells subsets in the spleen,
lung, and liver. We found that SLAMf6high NKT cells were enriched in NKT2 and
NKT17 cells, and subsequently demonstrate that iNKT cells from SLAMf6-/- mice
exhibit specific defects in IL-4 and IL-17 production that is associated with decreased
numbers of NKT2 and NKT17 cells in the thymus.
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2.3. Results
2.3.1 Distinct SLAM family receptor expression profiles on conventional αβ T and
iNKT cells
SLAM family receptors, together with the intracellular signaling adaptor molecule
SAP, are required for the development of iNKT cells (Chen et al., 2017; Chung et al.,
2005; Griewank et al., 2007; Kageyama et al., 2012; Nichols et al., 2005a; Sintes et al.,
2013). The function of SLAM family receptors on iNKT cells in the periphery, however,
is still mostly unclear. Since previous reports suggest that distinct SLAM family
receptors exhibit variable expression among NKT cells (Aktan et al., 2010), we assessed
the co-expression of three SLAM family receptors, SLAMf1, SLAMf4, and SLAMf6 on
iNKT cells and conventional  T cells among different organs in two different strains of
mice (Figure 1). This analysis revealed the presence of a unique pattern of SLAM family
receptor co-expression that distinguished iNKT cells from conventional  T cells, and
this pattern varied among different tissues (Figure 1). For example, we found that B6
spleen

iNKT

cells

were

SLAMf1intSLAMf4negSLAMf6pos.
SLAMf1negSLAMf4negSLAMf6neg,

primarily
In

SLAMf1negSLAMf4negSLAMf6pos

contrast,

B6

lung

iNKT

cells

SLAMf1negSLAMf4negSLAMf6pos,

or
were
or

SLAMf1posSLAMf4negSLAMf6pos. Conventional  T cells in the B6 spleen and lung, in
contrast, were primarily SLAMf1negSLAMf4negSLAMf6pos (Figure 1). We also noted that
while both iNKT cells and conventional  T cells expressed SLAMf6, a distinct
population of SLAMf6high iNKT cells could be observed in both the spleen and lung.
Since SLAM family receptor genes are polymorphic among inbred strains of mice, we
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also analyzed the patterns of SLAM co-expression on conventional T cells and iNKT
cells in the spleen, liver and lung in BALB/c mice (Figure 1). This analysis revealed
significant differences in SLAM family receptor co-expression in both iNKT cells and


T

cells

(Fig.

1).

Notably,

SLAMf1negSLAMf4negSLAMf6neg,

while

B6

lung

iNKT

cells

SLAMf1negSLAMf4negSLAMf6pos,

were
or

SLAMf1posSLAMf4negSLAMf6pos, we found that the majority of BALB/c lung iNKT
cells were SLAMf1negSLAMf4negSLAMf6pos (Figure 1). Similarly, we noted an increased
frequency of SLAMf1negSLAMf4negSLAMf6neg conventional  T cells in all organs
(Figure 1). Taken together, these data indicated the presence of a unique pattern of
SLAM family receptor co-expression that distinguished iNKT cells from their
conventional T cell counterparts and that these SLAM receptor expression profiles varied
significantly among different peripheral tissues and among different genetic backgrounds.

2.3.2 SLAM family receptor co-expression profiles define NKT cell subsets
The iNKT cell population is comprised of functionally distinct NKT1, NKT2, and
NKT17 subsets (Lee et al., 2013). Therefore, we asked whether the SLAM family
receptor co-expression profiles varied among the different iNKT cell subsets. iNKT cell
subsets are defined according to their expression of the transcription factors PLZF and
RORγt (Lee et al., 2013). NKT1 cells express low levels of PLZF and no RORγt. NKT2
cells express high levels of PLZF and no RORγt, and NKT17 express intermediate levels
of PLZF and RORγt (Figure 2A). Interestingly, analysis of splenic iNKT subsets revealed
distinct differences in the SLAM family receptor expression profile on each subset
63

(Figure 2A). NKT1 cells were primarily SLAMf1intSLAMf4lowSLAMf6int. All iNKT2
cells were SLAMf1lowSLAMf4lowSLAMf6high (Figure 2A). NKT17 cells were comprised
of two distinct populations, one that is SLAMf1highSLAMf4lowSLAMf6low, and a second
that is SLAMf1lowSLAMf4lowSLAMf6high (Figure 2A). These data demonstrated that
iNKT cell subsets were each characterized by a distinct SLAM family receptor
expression profile.
The frequency of NKT cell subsets varies among different organs (Lee et al.,
2015), and it has been reported that NKT1 cells are enriched in the liver, NKT2 cells in
the lung, and NKT17 cells in the lung and lymph node (Lee et al., 2015). Therefore, we
asked whether SLAM family receptor expression profiles on NKT cells also varied in an
organ-specific manner. We analyzed SLAM family receptor expression on the different
iNKT cell subsets in the spleen, lung, and liver of C57BL/6 and BALB/c mice (Figure
2B).

Interestingly,

we

found

SLAMf1highSLAMf4lowSLAMf6low

that

the

lung

was

enriched

SLAMf1lowSLAMf4lowSLAMf6high

and

in
cells

consistent with NKT17 cells (Figure 2B). Consistent with a previous report of tissue-and
strain-dependent variation in NKT cell subset frequencies (Lee et al., 2015), we observed
a greater frequency of NKT17 cells in the lungs of BALB/c mice and a concomitant
increase of SLAMf1highSLAMf4lowSLAMf6low iNKT cells (Figure 2B). Similarly,
BALB/c spleen and lung had an increased abundance of SLAMf6high NKT2 cells, and
livers of both strains were dominated by SLAMf1intSLAMf4lowSLAMf6int NKT1 cells
(Figure 2B). Taken together, these data suggest that SLAM family receptor expression
profiles stably mark functionally distinct NKT cell subsets in distinct peripheral tissues.
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2.3.3 SLAM family receptor co-expression profiles on iNKT cell subsets are
established during thymic development
NKT1, NKT2, and NKT17 subsets are established during thymic development
(Lee et al., 2013; Lee et al., 2015). Therefore, we asked whether the SLAM family
receptor expression profiles observed in the periphery were established coincident with
NKT cell subset development in the thymus. Analysis of CD4+CD8+ double positive
(DP) thymocytes, CD4 and CD8 single positive (SP) thymocytes, and NKT cells in the
thymus revealed that DP thymocytes were uniformly SLAMf1highSLAMf4lowSLAMf6high,
consistent with previous reports (Chen et al., 2017; Griewank et al., 2007; Jordan et al.,
2007a). Expression of SLAMf6 decreased significantly in CD4 and CD8 SP populations,
while SLAMf1 decreased only slightly (Figure 3A). In contrast to the homogeneous
SLAM family receptor expression on conventional T cells, thymic iNKT cells exhibited
distinct SLAM family receptor expression profiles. We observed a distinct
SLAMf1lowSLAMf4lowSLAMf6high

population,

as

well

as

a

SLAMf1lowSLAMf4highSLAMf6low population (Fig. 3A).
We next investigated whether the thymic SLAM family receptor profiles varied in
a strain-dependent manner as was observed in the peripheral tissues. Interestingly, we
noted an increased percentage of iNKT cells from C57BL/6 mice that were
SLAMf1negSLAMf4negSLAMf6neg (Figure 3B). Conversely, we observed an enrichment
of SLAMf6pos iNKT cells in BALB/c mice, consistent with increased NKT2 and NKT17
cells in this strain (Lee et al., 2015) (Figure 2B and 3E). Strain-dependent variation in
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SLAM family receptor expression profiles were not only confined to iNKT cells, as we
noted significant differences between C57BL/6 and BALB/c conventional αβ T cells
(Figure 3B). Taken together, these data suggested that the SLAM family receptor
expression profiles on iNKT cells and conventional T cells observed in the peripheral
tissues are established during thymic development and that the distinct expression
profiles are established upon divergence of the NKT and conventional  T cell lineages.
The classic developmental stages for thymic iNKT cells are defined by the
expression of CD44 and NK1.1 (Benlagha et al., 2002; Pellicci et al., 2002): Stage 1 is
CD44negNK1.1neg, Stage 2 is CD44highNK1.1neg, and Stage 3 is CD44highNK1.1high (Figure
3C/D). We confirmed recent reports that developmental stages defined by CD44 and
NK1.1 are roughly correlated with the NKT1, NKT2, and NKT17 subsets (Fig. 3C). We
next analyzed the SLAM family receptor co-expression on each of the iNKT cell stages.
We found that the SLAM family receptor expression patterns mirrored the expression
patterns we observed on the iNKT cells after gating with PLZF and RORγt in the
periphery (Figure 3D). Stage 1 iNKT cells expressed both SLAMf1 and SLAMf6 which
was indicative of both an NKT2 and NKT17 phenotype (Figure 3D). Stage 2 iNKT cells
express high SLAMf6, reminiscent of NKT2 cells (Figure 3D). Finally, the majority of
Stage 3 iNKT cells are low in both SLAMf1 and SLAMf6, with a subpopulation of cells
expressing SLAMf4 (Figure 3D), which is indicative of an NKT1 phenotype.
Finally, we assessed whether the distinct marking of iNKT cell subsets by SLAM
family receptor expression profiles was strain-dependent in the thymus as was observed
in the periphery. We found that the NKT1 subset in both strains exhibited two distinct
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populations, one that was SLAMf1intSLAMf4lowSLAMf6low and a second that was
SLAMf1lowSLAMf4highSLAMf6low (Fig. 3E). In contrast, NKT2 cells were characterized
by a SLAMf1lowSLAMf4lowSLAMf6high phenotype (Figure 3E). NKT17 cells in both
strains also showed two populations of cells, SLAMf1highSLAMf4lowSLAMf6high and
SLAMf1highSLAMf4lowSLAMf6low. Intriguingly, the SLAM family receptor expression
profiles in either C57BL/6 or BALB/c marked the same thymic iNKT cell subsets.
Together, these data suggest that the SLAM family receptor expression profiles that mark
functionally distinct NKT cell subsets in the periphery are established during thymic
development.

2.3.4 SLAMf6 deficiency results in a defect in NKT17 cells and IL-17 production
Given our findings that SLAMf6 was preferentially expressed on NKT2 and
NKT17 cells, we investigated whether SLAMf6 played a significant role in the
development of these specific NKT cell subsets. We first compared the number of iNKT
cell subsets between C57BL/6 and SLAMf6-/- mice. We observed a significantly lower
number of thymic NKT2 and NKT17, but not NKT1, subsets in SLAMf6-/- mice
compared to their C57BL/6 counterparts (Figure 4A). Analysis of the splenic NKT cell
subsets revealed a significant decrease in the number of NKT17, but not NKT1 cells
(Figure 4B). While there was a decrease in the number of iNKT2 cells in the spleen, this
did not reach statistical significance (Figure 4B). Therefore, these data suggested that the
NKT cell subsets on which SLAMf6 is preferentially expressed are present at
significantly lower numbers in SLAMf6-deficient mice.
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Next, we investigated whether SLAMf6-deficient mice exhibited an impaired
ability to produce NKT2 and/or NKT17 cytokines. We sorted spleen NKT cells from
C57BL/6 and B6.Slamf6-/- mice and cultured them for 72 h on anti-CD3-coated plates.
An analysis of NKT cell cytokine production revealed a significant decrease in the
production of IL-2 and IL-17 in SLAMf6-/- NKT cells (Figure 4C). We observed no
difference between the two mouse strains in IL-4, IL-5, or IL-13 production (Figure 4C).
These data indicated that SLAMf6-deficient NKT cells exhibited an impaired ability to
produce IL-17, consistent with the lower numbers of NKT17 cells in these mice. To
investigate whether NKT17 cells were impaired in their ability to produce IL-17, we
compared IL-17 production between B6 and B6.SLAMf6-/- NKT17 cells. To identify
NKT17 cells in B6.SLAMf6-/- mice, we used the surrogate markers ICOS (Cameron and
Godfrey, 2018; Engel et al., 2016) and NRP-1 (Milpied et al., 2011), which allowed us to
identify the NKT2 and NKT17 populations that also express high levels of SLAMf6
(Figure 4D). In our hands, we found that ICOShighNRP-1high cells contain the NKT2 and
NKT17 populations, while the ICOSlowNRP-1lowsubset contains the NKT1 cells (Figure
4D).
We sorted ICOSlowNRP-1low and ICOShighNRP-1high iNKT subsets from C57BL/6
and B6.SLAMf6-/- mice and assessed IL-17 production after culturing equal numbers of
cells for 72 h on anti-CD3-coated plates (Figure 4E). As expected, there was a low level
of detectable IL-17 produced in the ICOSlowNRP-1low population in both the wild-type
and B6.SLAMf6-/- mice, consistent with the prevalence of NKT1 cells in this population
(Figure 4E). Interestingly, IL-17 production in the ICOShighNRP-1high population was 2.5
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fold lower in the NKT17 cells from B6.SLAMf6-/- mice. More surprising was that the IL4 production from the ICOShighNRP-1high NKT2 and NKT17 B6.SLAMf6-/- population
was also significantly decreased (Figure 4E). Taken together, these data suggested that
SLAMf6 plays a critical NKT2/17 subset specific role in regulation of NKT IL-17 and
IL-4 production.
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2.4. Discussion
SLAM family receptors are widely expressed on all hematopoietic cells and
individual leukocyte populations are known to express a distinct, characteristic
complement of SLAM family receptors (Cannons et al., 2011). Here, we find that
examination of just 3 SLAM family receptors reveals distinct patterns of SLAM family
receptor co-expression that not only distinguish iNKT cells from their conventional αβ T
cell counterparts, but distinguish functionally distinct subsets of iNKT cells. Furthermore,
we find that these SLAM receptor expression profiles stably mark iNKT cell subsets in
naïve mice in different tissues and in different strains of mice. Our finding that the
development and function of SLAMf6high NKT2 and NKT17 subsets are dependent on
SLAMf6 indicates a segregation of SLAM receptor roles in regulating iNKT cell function
not previously appreciated. Indeed, these findings are reminiscent of a recent report
demonstrating that SLAM receptor expression profiles defined functionally distinct
populations of hematopoietic stem cells (Oguro et al., 2013). In addition, recent findings
from our laboratory indicate the presence of SLAM receptor expression profiles that
distinguish functional  subsets in mice (manuscript in preparation). These findings
demonstrate that the heterogeneity in SLAM family receptor expression is much greater
than previously thought, and suggest that discrete modulation of the array of SLAM
family receptors expressed by a cell may be a mechanism used to fine-tune cell function.
Despite the critical role played by the SLAM/SAP signaling pathway in iNKT
cell development, elucidation of the specific functions regulated by individual SLAM
family receptors has proven difficult. While deletion of multiple SLAM family receptors
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results in impaired iNKT cell function (Hu et al., 2016), it has been difficult to identify
significant impairments in iNKT cell function in mice deficient in only a single SLAM
family receptor. One study using an inducible conditional SAP knockout mouse to delete
SAP after iNKT cells had developed, reported that deletion of SAP had no effect on IFN or IL-4 production and found a defect only in iNKT cell cytotoxicity (Das et al., 2013).
Our data demonstrating that SLAMf6 specifically regulates NKT2 and NKT17, but not
NKT1, is consistent with this finding since most iNKT cell cytotoxicity is mediated by
NKT1 cells. In addition, our data indicate that after in vivo αGalCer administration, the
vast majority of IL-4 is produced by the predominant NKT1 population and not by the
minor NKT2 population (data not shown), providing a possible explanation for why this
defect was not previously observed. This would be consistent with a recent report
demonstrating that all thymic iNKT subsets, including NKT1 cells, can produce IL-4
after stimulation (Cameron and Godfrey, 2018; Georgiev et al., 2016; Tang et al., 2014).
Using a Vα14 transgenic mouse to force iNKT cell development in the absence of
SAP, Michel et al., demonstrated that iNKT cells developing in the absence of SAP
exhibited a marked defect in NKT2 cells but an expansion of NKT17 cells (Michel et al.,
2016). These data are in partial agreement with our observation that mice deficient in
SLAMf6, which signals using the SAP adapter, are also deficient in NKT2 cells. While
our data differed in that we observed a reduction in NKT17 cells, this discrepancy could
be due to either the different experimental approaches used, or it could point to the
involvement of additional SLAM family receptors in the regulation of the NKT17 subset.
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Studies using SLAMf1/5/6 triple knockouts demonstrated significantly reduced
numbers of iNKT cells versus those observed in SLAMf6–deficient mice (Huang et al.,
2016), suggesting that SLAMf1, SLAMf5, and SLAMf6 can each contribute to the
positive signaling required for iNKT cell development (Chen et al., 2017). Our data,
combined with these previous reports, suggest that SLAMf6 may have the greatest effect
on the development of NKT2 and NKT17 cells while SLAMf1 and SLAMf5 may affect
NKT1 cells specifically, or provide compensatory signaling in the absence of SLAMf6
on this subset.
Our data suggest that SLAMf6 has a specific effect on iNKT cell IL-17
production. Unlike the case with IL-4, which can be produced by NKT1 and NKT2 cells
after stimulation by αGalCer, we found that only NKT17 cells produced IL-17 consistent
with a recent report (Cameron and Godfrey, 2018). SLAMf6 has previously been
implicated in the production of IL-17 (Tang et al., 2014). In a study comparing the
cytokine production of splenic IL-17 producing iNKT cells, SLAMf6lowCD4negNK1.1neg
NKT17 cells produced IL-17, whereas SLAMf6highCD4posNK1.1neg produced IL-21.
While the reason for these discrepant findings is not clear, they may result from the use in
that study of autoimmune-prone NZB/W mice. In addition, we note that a small
percentage of CD4negSLAMf6high cells, which comprise up to 30-50% of the NKT17 cells
in the spleen (Cameron and Godfrey, 2018), were not analyzed (Tang et al., 2014).
Slam family genes are highly polymorphic and these polymorphisms are known
to have functional consequences. Recently, it was shown that mice that possess Slam
haplotype 2 as opposed to Slam haplotype 1 alleles exhibit a decreased NKT1/NKT2
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ratio while the NKT17 subset was unaffected (Baglaenko et al., 2017). There are
profound differences in the level of SLAM receptor expression as well as receptor
signaling capabilities between the Slam haplotypes (Wandstrat et al., 2004). For example,
Slam haplotype 1 contains an isoform for SLAMf6 that is more inhibitory than the
isoform present in Slam haplotype 2 expressing animals (Keszei et al., 2011). SLAMf1
and SLAMf6 receptor expression is decreased in Slam haplotype 2 animals, while
SLAMf3 expression is increased (Baglaenko et al., 2017). Our data demonstrating that
SLAMf6 plays a role in NKT2 development suggests the possibility that the straindependent differences in NKT2 subsets result from the differing signaling capabilities of
the SLAMf6 isoforms expressed in each of these strains.
Together, our data linking SLAM family receptor expression profiles with
functional iNKT cell subsets provides a new conceptual framework that may help
elucidate the specific roles of SLAM family receptors on iNKT cells as well as other
leukocyte subsets. Specifically, the data demonstrating that SLAMf6 specifically
regulates NKT2 and NKT17 development could represent an important link in our
understanding the connection between iNKT cell development and iNKT cell functional
programming.
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2.5. Materials and Methods

2.5.1 Mice and Reagents
Female C57BL/6 and BALB/cJ mice were purchased from The Jackson
Laboratory (Bar Harbor, ME) and were bred at the University of Vermont. SLAMf6-/mice were described previously (Dutta et al., 2013). Mice were bred and housed in the
specific pathogen-free barrier facility at the University of Vermont. All procedures
involving animals were approved by the University of Vermont Institutional Animal Care
and Use Committee.

2.5.2 Flow cytometry
Splenocytes and thymocytes were obtained by gently pressing through a 70 m
nylon mesh. Liver leukocytes were obtained by gently pressing through a 70 µm nylon
mesh, followed by washing in PBS, and separation of hepatocytes via a 33.8% Percoll
gradient (GE Healthcare, Chicago, IL) as described (Rymarchyk et al., 2008). Lung
leukocytes were isolated via mechanical dissociation followed by enzymatic degradation
using 200µg/mL DNAse (Sigma Aldrich, St. Louis, MO) and 1mg/mL Collagenase Type
IV (Life Technologies, ThermoFisher, Waltham, MA) as described (Benoit et al., 2015).
RBC’s were lysed using Gey’s solution. Cells were stained at 4°C in PBS + 2% FBS
containing 0.2% sodium azide for 30 min., after which they were washed and
resuspended in PBS + 1% PFA when appropriate. Surface antibodies used in these
studies were anti-CD16/32 (Fc block), CD4, CD45, TCRβ, NK1.1, Nkp46, CD8,
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SLAMf1, SLAMf4, SLAMf3, SLAMf2, SLAMf5, SLAMf6, ICOS, and NRP-1
(Biolegend, San Diego, CA). Additional antibodies CD11b, CD19, and CD44 were
obtained from BD biosciences. UV Live Dead staining reagent was included in all
experiments (Life Technologies, ThermoFisher, Waltham, MA). CD1d tetramer loaded
with PBS-57 was provided by the National Institutes of Health (NIH) tetramer facility
(Emory University Vaccine Center, Atlanta, GA).
For nuclear transcription factor staining, cells were surface stained as above, after
which they were fixed overnight using the Foxp3 transcription factor staining buffer set
(EBiosciences, ThermoFisher, Waltham, MA). The next day cells were washed, blocked
with rat IgG, and stained with anti-PLZF (9E12) and RORγt (Q31-378) (BD
Biosciences). After staining, cells were washed, resuspended, and data were immediately
collected on a LSRII flow cytometer (BD Biosciences, Franklin Lake, NJ) and analyzed
with FlowJo software (FlowJo LLC).

2.5.3 Analysis of SLAM receptor expression patterns
Three-way analysis of SLAM receptor expression was performed with
combinatorial gating using FlowJo software (FlowJo LLC). In brief, iNKT cells were
first identified using anti-TCRβ and CD1d tetramer. Positive SLAMf1, SLAMf4, and
SLAMf6 gates were identified using specific SLAM fluorescence minus-one controls.
Combination gates were then applied for the positive gates resulting in multiple
combination averages of the permutations of SLAM receptor expression on iNKT cells.
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When appropriate, percent expression for multiple mice were averaged and plotted in
GraphPad Prism (GraphPad Software, San Diego, CA).

2.5.4 Statistics
All animal experiments were conducted in a non-randomized and non-blinded
fashion. Statistical analyses were performed using an unpaired T test or multiple T tests
where appropriate. In all cases, tests were considered significant when p ≤ 0.05. All
groups were shown to have similar variance in distribution. Sample size estimates were
based on previous experience. When data were combined from multiple different
experiments, data were first normalized to the C57BL/6 reference strain in each
experiment. Normalization was accomplished by dividing each data point in an
experiment by the average of the C57BL/6 response in that experiment. All statistical
analysis was performed using Graph Pad Prism (GraphPad Software, San Diego, CA).

2.5.5 Cell isolation and culture for ex vivo cytokine analysis
Splenocytes were enriched for NKT cells using the STEMCELL EasySep CD4+
negative selection kit according to the manufacturer’s instructions. After which, cells
were stained with Live/Dead efluor780 (EBiosiences), anti-TCRβ, CD11b, CD8, Nkp46,
ICOS and NRP-1, and the addition of CD1d/PBS-57 loaded-tetramer. NKT cells were
subsequently purified by fluorescent activated cells sorting (FACS Aria III). Cell purity
for all sorts was between 80% and 95%. After sorting, cells were placed in modified
Click’s culture medium (5% FBS, 2mM glutamine, Pen/Strep, 50µM 2-mercaptoethanol,
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20µg/mL gentamycin) and incubated on anti-CD3 (5 g/ml) and anti-CD28 (1 g/ml)coated plates at 37 oC and 5% CO2. 72 h later, supernatants were harvested and analyzed
via Milliplex assay or ELISA, according to the manufacturer’s instructions (EMD
Millipore, Darmstadt, Germany).

The milliplex kits used were the Mouse

cytokine/chemokine magnetic bead panel followed by a custom kit containing GM-CSF,
IFNγ, IL-2, IL-4, IL-5, IL-10, IL-13, and IL-17.

2.5.6 ELISA
Interleukin-4 and IL-17 ELISAs were performed on cultured supernatants from
sorted NKT cell cultures as above. IL-4 capture was plated on a COSTAR high protein
binding plate overnight at 4°C. After which, the plate was washed, blocked, and
detection, strep-HRP, TMB substrate, and stop solution added after the appropriate
incubations. All IL-4 reagents were obtained from Biolegend. TMB substrate was from
BD Biosciences. IL-17 ELISA was performed via the R&D mouse IL-17 Duo kit
according to the manufacturer’s instructions (R&D Systems, Minneapolis, MN).
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2.8. Figures
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FIGURE 2-1: Strain-dependent and organ-specific heterogeneity in SLAM family
receptor co-expression profiles on iNKT cells.

Representative contour plots of SLAMf1, SLAMf4, and SLAMf6 receptor expression on
spleen, liver, and lung conventional αβ T cells and iNKT cells from B6 (upper) and
BALB/c mice (lower). iNKT cells and conventional αβ T cells were identified using
CD1d-tetramer/PBS57 and TCRThree-way expression profiles of the different SLAM
receptors were calculated using combination gating and are presented as a percentage of
total iNKT or αβ T cells. Data is representative of 4 separate experiments using B6 mice
(n =18 mice), and 2 separate experiments using BALB/c mice (n = 10 mice).
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FIGURE 2-2: SLAM family receptor co-expression marks iNKT cell subsets in
peripheral tissues.

iNKT cell subsets from the spleen, lung, and liver were identified using CD1dtetramer/PBS57 and TCRβ followed by staining for transcription factors. A). SLAM
family receptor expression profiles on spleen iNKT cell subsets. Top: Gating scheme
used for identification of iNKT cell subsets using PLZF and RORγt expression. Bottom:
Co-expression of SLAMf1, SLAMf4, and SLAMf6 on iNKT1 (green), iNKT2 (red), and
iNKT17 (blue) subsets. B). Strain-dependent and organ-specific heterogeneity in SLAM
receptor co-expression profiles on iNKT cell subsets. Representative flow cytometry
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comparing SLAMf1, SLAMf4, and SLAMf6 receptor expression in C57BL/6 mice (top)
and BALB/c mice (bottom). Overlays of NKT1 (grey), NKT2 (red), and NKT17 (blue)
subsets reveal that SLAM family receptor expression profile marking of NKT cell subsets
are relatively stable amidst strain-dependent and organ-specific variability in the
frequency of NKT cell subsets. Data is representative of 4 separate experiments using B6
mice (total of 18 mice), and 2 separate experiments using BALB/c mice (total of 10
mice). All mice were age- and sex-matched in each experiment.
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FIGURE 2-3: SLAM family receptor expression profiles are established during
thymic development.
Thymic iNKT cells and conventional  T cells from C57BL/6 or BALB/c mice were
identified using TCRβ and CD1d-tetramer/PBS-57 or CD4 and CD8, respectively. A).
Representative flow cytometry plots of SLAM family receptor expression profiles on
C57BL/6 thymic CD4+, CD8+, DP, and iNKT cells. Examination of SLAMf1, SLAMf4,
and SLAMf6 co-expression revealed heterogeneous co-expression on iNKT cells but not
conventional T cells. B). Cumulative SLAM family receptor co-expression profiles on
thymic iNKT and conventional T cells from C57BL/6 and BALB/c mice. C). iNKT cell
subset profiles correlate with C57BL/6 iNKT cell developmental stages. Representative
flow cytometry of iNKT subsets identified using PLZF and RORγt, followed by analysis
of CD44 versus NK1.1 expression. D). Distinct SLAM family receptor expression
profiles associated with NKT cell developmental stages. Thymic NKT cells were
identified using TCR and CD1dtetramer/PBS57, then stained with CD44 and NK1.1 to
identify classical NKT cell developmental stages and SLAMf1, SLAMf4, and SLAMf6
expression was evaluated. Representative flow cytometry of SLAMf1, SLAMf4, and
SLAMf6 co-expression on Stage 1 (blue), Stage 2 (red), and Stage 3 (green) iNKT cells.
E). Strain-dependent SLAM family receptor expression profiles are established during
thymic development. Representative flow cytometry plot overlays of SLAMf1, SLAMf4,
and SLAMf6 expression on NKT1 (grey), NKT2 (red), and NKT17 (blue) subsets. Data
are representative of 2 separate experiments, n= 9 mice per strain per experiment. Mice
were age- and sex- in each experiment.
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FIGURE 2-4: SLAMf6-dependent NKT2 and NKT17 development and function.

A). Decrease in thymus iNKT2 and iNKT17 subsets in SLAMf6-/- animals. Top:
Representative flow cytometry plots of thymic iNKT cell subsets defined using PLZF and
RORγt staining. Subsets are indicated by colored boxes: NKT1 (green), NKT2 (red), and
NKT17 (blue). Bottom: Relative number of iNKT cell subsets in B6 and SLAMf6-/animals. Data are the cumulative quantification of 4 separate experiments. Statistical
analysis was performed using an unpaired T test. *p ≤ 0.05 **p ≤ 0.01 B). Decrease in
spleen NKT17 cells in SLAMf6-/- animals. Upper: Representative flow cytometry of
iNKT cells and iNKT cell subsets between C57BL/6 and SLAMf6 -/- animals identified as
above. Lower: Relative number of total splenic iNKT cells and iNKT cell subsets
between B6 and SLAMf6-/- animals. Data are the cumulative quantification of 4 separate
experiments. Statistical analysis was performed using an unpaired T test. **p ≤ 0.01 C).
NKT-intrinsic reduction in IL-17 production from SLAMf6-/- iNKT cells. iNKT cells
from C57BL/6 and SLAMf6-/- animals were sorted and incubated on anti-CD3-coated
plates for 72 h, after which supernatant cytokine levels were assessed using Milliplex.
Data represent the cumulative results of 2 separate experiments. Statistical analysis was
performed using an unpaired T test. *** p ≤ 0.001, ****p ≤ 0.0001 D). Confirmation of
NKT2-specific surrogate markers ICOS and NRP-1 for use in sorting. Top: iNKT cell
subsets (shown in colored boxes) were evaluated for ICOS, NRP-1, and SLAMf6
expression. All three proteins marked NKT2 and NKT17 subsets. Bottom: Gating
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strategy for isolating specific iNKT1 versus iNKT2 and iNKT17 subsets using ICOS and
NRP-1. Representative flow cytometry of iNKT cells identified using CD1dtetramer/PBS57 and TCRβ. Middle: ICOShighNRP1high identify NKT2 and NKT17 cells
while ICOSlowNRP1low identify NKT1 cells in both C57BL/6 and SLAMf6-/- mice. E).
Significantly reduced IL-17 and IL-4 production from sorted ICOShighNRP-1high
NKT2/NKT17 subsets in Slamf6-/- mice. Sorted NKT2/NKT17 and NKT1 subsets were
stimulated on anti-CD3-coated plates for 72hrs. IL-4 and IL-17 production from
supernatants were determined via ELISA. Data are representative of 2 separate
experiments. Statistical analysis was performed using multiple T tests. **p ≤ 0.01 ****p
≤

0.0001.
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3.1. Abstract

Semi-invariant natural killer T cells (iNKT) are important mediators of host
immunity. This innate-T cell subset is now thought to encompass specific subsets
responsible for the production of IFNγ (NKT1), IL-4 (NKT2), and IL-17 (NKT17).
While these cell subsets are distinct within the thymus, less is known about the regulation
of iNKT cell subsets in the periphery. Regulation of iNKT cells in general is thought to
occur via the signaling lymphocyte activation markers (SLAMs), which are required with
the SLAM family receptor adaptor protein (SAP) for the development of iNKT cells. A
complete analysis of SLAM family receptors on iNKT cell subsets has not been
completed. Here, we show that SLAMf6, which can have both activating and inhibitory
function on iNKT cells, is responsible for cytokine production and the proliferation of
NKT2 and NKT17 subsets after activation. Additionally, we show preferential expansion
of an NKT2 cell like population 3 days after activation with the iNKT cell agonist
αGalCer. These data reveal a role for SLAMf6 on the regulation of distinct NKT2 and
NKT17 subsets in the periphery. Our data also challenge the definitions of iNKT cell
subsets, revealing potential changes to the iNKT cell milieu after activation. Taken
together, these data improve our understanding of the mechanisms regulating NKT1,
NKT2, and NKT17 behavior upon activation in the periphery.
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3.2. Introduction
Invariant natural killer T (iNKT) cells are innate-like T cells that play critical
roles in the host immune response (Behar and Porcelli, 2007; Godfrey and Rossjohn,
2011; Gumperz and Brenner, 2001). iNKT cells recognize glycolipids bound by the MHC
class-1 like molecule CD1d (Kawano et al., 1997; Spada et al., 1998). When activated by
the prototypical agonist alpha-galactosylceramide (αGalCer), iNKT cells produce a wide
variety of cytokines such as IFNγ, IL-4, TNFα, IL-17, and IL-10 (Coquet et al., 2008;
Hameg et al., 2000; Yoshimoto and Paul, 1994). During iNKT cell development, three
distinct iNKT cell subsets have been described: NKT1, which produces IFN- and is
characterized by low PLZF and high T-bet expression, NKT2, which produces IL-4, IL-5,
and IL-13 and is characterized by high PLZF expression, and NKT17, which produces
primarily IL-17 and is characterized by high RORt expression (Lee et al., 2013; Lee et
al., 2015).
NKT cell development is highly dependent on signaling by multiple SLAM
family receptors and their associated signal adapter protein SAP (Griewank et al., 2007;
Nichols et al., 2005a; Sintes et al., 2013). The best characterized interactions are
SLAMf1-SLAMf1 and SLAMf6-SLAMf6 interactions that are thought to occur between
developing iNKT cells and neighboring DP thymocytes that express high levels of both
of these proteins as well as CD1d (Coles and Raulet, 2000; Gapin et al., 2001; Griewank
et al., 2007). Multiple engagements of different SLAM family receptors appear to be
necessary for iNKT cell development as mice deficient in either SLAMf1 or SLAMf6
alone are able to mediate selection of iNKT cells, albeit to lower levels than their wild95

type counterparts (Griewank et al., 2007; Huang et al., 2016). Although SLAM family
receptor signaling is critical for iNKT cell development, the exact mechanisms through
which they act is still unclear. Accumulating data suggest that SLAMf6 induces the
expression of PLZF and Egr2, transcription factors critical for iNKT cell development
(Baglaenko et al., 2017; Dutta et al., 2013; Tuttle et al., 2018). However, it has also been
reported that SLAMf6 possesses inhibitory functions that are modulated by the SAP
signaling adapter (Kageyama et al., 2012). Finally, very little is known about the role of
SLAMf6 in regulation of the development of different iNKT cell subsets and how this
affects iNKT cell function in peripheral tissues.
We have previously shown that SLAMf1, SLAMf4, and SLAMf6 are coexpressed in a heterogeneous manner among different iNKT cell subsets (Chapter 2). We
found that SLAMf6 was highly expressed on all NKT2 cells and a significant fraction of
NKT17 cells, and that SLAMf6 regulated IL-17 and IL-4 cytokine production from
NKT17 and NKT2 subsets, respectively (Chapter 2). We next examined whether
SLAMf6 could also affect the proliferation of iNKT cells in a subset specific manner.
Here, we report that the SLAMf6-expressing NKT2 and NKT17 subsets in the
peripheral tissues encompass the majority of the proliferating NKT cells both in vivo and
in vitro. Ki67 and BrdU+ NKT cells are highly enriched in SLAMf6high NKT2 and
NKT17 cells. Using surrogate markers ICOS and NRP-1 for NKT2 and NKT17 (without
the use of SLAMf6), we showed that NKT2 and NKT17 cells are also more proliferative
than NKT1 cells in the B6.SLAMf6-/- mouse. Interestingly, SLAMf6 deficient NKT2 and
NKT17 cells did not proliferate to the same level as C57BL/6 iNKT cells. Finally, we
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show that NKT2 cells may preferentially expand after activation with the prototypical
glycolipid alpha-galactosylceramide (αGalCer). This manuscript supports a model in
which SLAMf6 has multiple roles on iNKT cells subsets, not only in activation of
cytokine production, but also in maintenance of iNKT cell subset homeostasis.
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3.3. Results

3.3.1 SLAMF6 marks highly proliferative NKT2 and NKT17 cells
To investigate the proliferative capacity of thymic iNKT cells, we assessed the
expression of Ki67, a marker of cells in either the S or G2/M phase of the cell cycle, on
thymic iNKT cell subsets. A comparison of naïve thymic iNKT cell subsets in the
C57BL/6 mouse (Figure 1A) revealed significant differences in Ki67 expression among
NKT1, NKT2, and NKT17 subsets. Whereas high levels of Ki67 expression were
observed in the NKT2 and NKT17 subsets, little Ki67 expression was observed in the
NKT1 subset which comprises the majority of thymic iNKT cells (Figure 1A).
Calculation of the frequency of Ki67+ iNKT cells revealed that a significantly higher
percentage of NKT2 and NKT17 cells were Ki67+ (Figure 1A), indicating that the thymic
NKT2 and NKT17 subsets constitute the highly proliferative iNKT cells in the thymus.
Since we previously observed that the population of SLAMf6high NKT cells in the
thymus was composed primarily of NKT2 and NKT17 subsets (Chapter 2), we
investigated the association of SLAMf6 expression with Ki67. An analysis of total
thymic iNKT cells revealed a clear correlation between high SLAMf6 expression and
Ki67 expression (Figure 1B). These data indicated that the vast majority of proliferating
Ki67+ NKT cells in the thymus were SLAMf6high NKT2 and NKT17 cells.
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3.3.2 SLAMf6 marks highly proliferative peripheral NKT2 and NKT17 cells after
activation
We next investigated whether SLAMf6 expression on iNKT cells in peripheral
tissues was associated with proliferative capacity. First, we confirmed that SLAM6high
iNKT cells marked the NKT2 (PLZFhighRORtlow) and NKT17 (PLZFintRORthigh)
subsets while SLAMf6low iNKT cells marked the NKT1 (PLZFlowRORtlow) and NKT17
spleen iNKT cells (Figure 2A). To determine whether there was a difference in the
proliferative capacity of the SLAMf6high (NKT2/NKT17) cells and SLAMf6low
(NKT1/NKT17) iNKT cells, we sorted spleen iNKT cells based on their SLAMf6
expression (Supplementary Figure 1) and assessed their proliferation after anti-CD3
stimulation. FACS-sorted iNKT cell subsets were labelled with VioTracker fluorescent
dye and cultured for three days on anti-CD3-coated plates after which we assessed
proliferation (Figure 2B). Interestingly, we observed a significantly higher number of live
SLAMf6high iNKT cells versus their SLAMf6low counterparts, and we found that
SLAM6high iNKT cells had proliferated significantly more than the SLAMf6low iNKT
cells (Figure 2B). The association of SLAMf6 with increased proliferative capacity was
not specific to C57BL/6 NKT cells, as we also observed increased proliferation in
SLAMf6high iNKT cells from BALB/c mice (Supplementary Figure 2). Taken together,
these data indicate that SLAMf6 expression marks NKT2 and NKT17 cells that are
homeostatically proliferating in vivo, and that SLAMf6 expressing NKT2/NKT17 cells
exhibit a significantly higher proliferative capacity than their SLAM6low NKT1
counterparts after stimulation.
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3.3.3 Expansion of SLAMf6high NKT2-like cells after in vivo activation
Next, we evaluated the relationship of SLAMf6 expression on iNKT cells and
proliferation in vivo after activation with the more physiological CD1d ligand, αGalCer,
which induces rapid proliferation of NKT cells (Kawano et al., 1997) (Supplementary
Figure 3). First, we assessed SLAM family receptor expression on iNKT cells 3 and 5
days afterαGalCer administration. This analysis revealed a 12.5-fold increase in the
expression of SLAMf6 on NKT cells 3 days after activation (Figure 3A). In contrast, we
observed a 3.5 and 3.2 fold increase in SLAMf1 and SLAMf3 expression respectively at
this time (Figure 3A). Interestingly, while iNKT cell SLAMf6 expression in naïve mice
was quite heterogeneous, SLAMf6 expression was uniformly high 3 days after activation
and cells retained this level of expression 5 days after activation (Figure 3A), at which
time iNKT cell numbers were returning to baseline levels (Supplementary Figure 4). In
contrast, the expression of SLAMf1 and SLAMf3 had returned to baseline levels 5 days
after activation. These data reveal that after activation and expansion of iNKT cells, the
iNKT cell population is dominated by SLAMf6high iNKT cells.
Since we have shown that SLAMf6 is preferentially expressed on naïve NKT2
and NKT17 cells, we next determined whether the SLAMf6high iNKT cells present on day
3 exhibited an NKT2 phenotype. A comparison of splenic iNKT cell subsets between
vehicle-treated and αGalCer-treated mice revealed a dramatic increase in a population of
PLZFhighRORγtlowSLAMf6high iNKT cells (Figure 3B), which was reminiscent of the
phenotype of NKT2 cells. To determine the proliferative capacity of the iNKT cell
subsets in vivo, we assessed BrdU incorporation after αGalCer administration. B6 mice
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were challenged with αGalCer i.p., BrdU was administered 48 h later, and iNKT BrdU
incorporation was assessed 72 h after αGalCer administration. After 72hrs, iNKT cells
showed increased proliferation, with 20% of all iNKT cells actively incorporating BrdU
at this time point (Figure 3C). Interestingly, the only cells that were actively
incorporating BrdU were the PLZFhigh iNKT cells (Figure 3C). Together, these data
suggested that a PLZFhigh SLAMf6high NKT2-like population of iNKT cells preferentially
expanded after activation in vivo. Whether these cells are, in fact, NKT2 cells remains
unclear since an analysis of the NKT1-specific transcriptional regulator T-bet revealed
that it was also highly expressed in the PLZFhigh SLAMf6high “NKT2-like” population of
iNKT cells 3 days after activation (data not shown), raising the possibility that altered
expression of the diagnostic PLZF, RORt, and T-bet transcription factors after activation
may preclude their use for identification of iNKT cell subsets.

3.3.4 Slamf6-dependent proliferation of NKT2/NKT17 subsets
Since our data indicated that SLAMf6 expression was closely associated with
iNKT cell proliferation in vivo and in vitro, we next investigated whether SLAMf6
regulated iNKT cell proliferation by assessing the proliferative capacity of SLAMf6deficient iNKT cell subsets. Since our previous results suggested that identification of
iNKT cell subsets in vivo after activation was difficult, we compared proliferation in vitro
using anti-CD3 stimulation. To identify iNKT cell subsets in both C57BL/6 and
B6.SLAMf6-/- mice, we employed the previously identified surrogate markers ICOS
(NKT2) and NRP-1 (NKT2 and NKT17) (See Chapter 2, Figure 4D) that we
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demonstrated reproducibly distinguished the NKT1 subset from the NKT2/NKT17
subsets in both B6 and B6.SLAMf6-/- mice (Chapter 2).
We sorted ICOShighNRP-1high (NKT2/NKT17) and ICOSlowNRP-1low (NKT1)
splenic iNKT cells, stimulated equal numbers of cells with anti-CD3 and anti-CD28, and
assessed the number of viable cells after 72 hours. As expected, we observed a
significantly higher number of live ICOShighNRP-1high NKT2/NKT17 cells compared to
their ICOSlowNRP-1low NKT1 counterparts (Figure 4). Interestingly, we observed a
striking decrease in the number of the ICOShighNRP-1high NKT2 cells in B6.SLAMf6-/mice compared to their C57BL/6 counterparts (Figure 4). Taken together, these data
reveal a specific role for SLAMf6 in the regulation of SLAMf6high NKT2/NKT17 iNKT
cell proliferation after activation.
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3.4. Discussion
SLAM family receptors and the signaling adapter protein SAP play critical roles
in iNKT cell development (Griewank et al., 2007; Kageyama et al., 2012; Nichols et al.,
2005a). However, elucidation of the specific roles that individual SLAM family receptors
play in iNKT cells has been difficult. Here, we show that SLAMf6 is highly expressed on
homeostatically proliferating iNKT cells that we identify as NKT2 and NKT17 subsets.
In addition, we demonstrate that SLAMf6 controls activation-induced proliferation of
NKT2 and NKT17, but not NKT1, subsets. These data not only reveal a specific role for
SLAMf6 in iNKT cell function, but also indicate that functions of individual SLAM
family receptors are not evenly distributed among each of the iNKT cell subsets.
Our finding that SLAMf6 controls the proliferation of NKT2 and NKT17 subsets
is consistent with recent transcriptomic studies of thymic iNKT cell subsets which found
that the NKT2 subset is enriched in both SLAMf6 and cell cycle gene transcripts (Engel
et al., 2016; Georgiev et al., 2016). In addition, recent reports demonstrate that thymic
NKT2 and NKT17 cells are significantly more proliferative than their NKT1 counterparts
(Cameron and Godfrey, 2018) and that all iNKT cell subsets pass through an IL-13expressing (i.e., NKT2-like) intermediate during thymic development (O'Brien et al.,
2016). These studies suggest that the NKT2 and NKT17 subsets may represent a cycling
population that is a precursor to the NKT1 subset (Engel et al., 2016; Lee et al., 2015).
Together with these findings, our data suggests that SLAMf6 may function at an early
stage of thymic development to foster cycling and expansion of the NKT2 and NKT17
subsets. Our data are not consistent, however, with a model in which NKT2 and NKT17
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subsets are precursors to NKT1 cells since the absence of SLAMf6 did not have
significant impact on the NKT1 subset.
Consistent with its proliferative phenotype, we observed an increase in an
“NKT2-like” population of iNKT cells 3 days after αGalCer administration. These cells
expressed high levels of PLZF and SLAMf6, but also expressed high levels of T-bet,
making an unambiguous NKT subset identification difficult. The expanded iNKT cells
could be NKT1 cells exhibiting increased PLZF expression after activation, but most
reports suggest that PLZF is only induced after TCR signaling in the thymus and is not
inducible on mature T cells (Savage et al., 2011; Zhang et al., 2015). While T-bet is
widely used as a marker of NKT1 cells, a population of PLZFhighTbethigh NKT2
precursors has been described (Engel et al., 2016; Pellicci et al., 2002), which could
represent the SLAMf6high NKT subset that we observe in the spleen 3 days after
activation.
Whether highly proliferative SLAMf6high NKT2 cells preferentially expand in
the periphery or whether they represent recent thymic emigrants is unclear. NRP-1 which
is highly expressed on the SLAMf6high NKT2 and NKT17 subsets has been suggested to
mark recent thymic emigrants (Milpied et al., 2011), and it was demonstrated that NKT2
cells express more homing markers than do NKT1 cells, and that NKT2 and NKT17
emigrate from the thymus at higher rates than NKT1 (Georgiev et al., 2016). After
activation with αGalCer, iNKT cells either downregulate their TCR or undergo activation
induced cell death (Subleski et al., 2011; Wilson et al., 2003). Liver iNKT cells, which
are comprised of primarily NKT1 cells (Lee et al., 2015), appear to rapidly undergo cell
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death within 24 h of αGalCer treatment, which is followed by repopulation of the liver
with iNKT cells that are ICOShighTCRβhighNK1.1neg, a phenotype consistent with what we
now know are NKT2 cells (Subleski et al., 2011). We report here that these repopulating
cells also expressed high levels of SLAMf6, another marker of NKT2 cells. Additional
experiments will be needed to determine the relative contributions of the proliferation of
peripheral iNKT cells and contributions from the recent thymic emigrant pool in the
SLAMf6-dependent proliferation of iNKT cells.
Regulation provided by SLAMf6 is thought to occur at the immunological
synapse upon TCR engagement (Tuttle et al., 2018; Zhao et al., 2012). A recent report
observed that SLAMf6 crosslinking is required for the upregulation of Egr2, a protein
activated downstream of TCR engagement (Tuttle et al., 2018). Once Egr2 expression
reached a sustained, high level, PLZF expression was induced, allowing for the
differentiation of iNKT cell subsets (Dutta et al., 2013; Tuttle et al., 2018). These data are
consistent with previous reports revealing SLAMf6 as an inducer of PLZF on double
positive thymocytes (Dutta et al., 2013). Interestingly, we did not see any significant
differences in PLZF expression between C57BL/6 and SLAMf6-/- iNKT cell subsets in
either the thymus or the spleen (Supplementary Figure 4), suggesting the possibility that
other SLAM receptors may be compensating in the absence of SLAMf6.
Although it has been known for some time that both SLAMf1 and SLAMf6
contribute to iNKT cell development (Griewank et al., 2007), the relative contributions of
these SLAM receptors has been difficult to define. In this manuscript, we demonstrate a
link between SLAMf6 that is highly expressed on NKT2 and NKT17 cells and their
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increased proliferative capacity. Our finding that SLAMf6 primarily regulate NKT2 and
NKT17 proliferation suggests the possibility that the requirement for both SLAMf1 and
SLAMf6 may not simply be due to their additive effects. Rather, each SLAM receptor
may play a distinct role in iNKT cell development. These observations may aid in our
understanding of how NKT cell subsets develop and proliferate in tissues,b which may
have important consequences on tissue-specific immunity.
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3.5. Materials and Methods

3.5.1 Mice and reagents
C57BL/6 and BALB/cJ mice were obtained from The Jackson Laboratory (Bar
Harbor, ME). B6.Slamf6-/- mice have been described previously (Dutta et al., 2013).
Mice were bred in the specific pathogen free barrier facility at the University of Vermont.
All procedures involving animals were approved by the University of Vermont
Institutional Animal Care and Use Committee. αGalCer (Avanti Lipids) was resuspended
in PBS + 0.05% Tween20, and administered to mice intraperitoneally (i.p.).

3.5.2 Flow cytometry
Splenocytes and thymocytes were obtained by gently pressing through a 70 m
nylon mesh. Splenic red blood cells were lysed using Gey’s solution. Cells were stained
at 4°C in PBS + 2% FBS containing 0.2% sodium azide for 30 min., after which they
were washed and resuspended in PBS + 1% PFA when appropriate. Surface antibodies
used in these studies were anti-CD16/32 (Fc block), CD4, CD45, TCRβ, NK1.1, Nkp46,
CD8, SLAMf1, SLAMf3, SLAMf6, ICOS, and NRP-1 (Biolegend, San Diego, CA).
CD11b and CD19 antibodies were obtained from BD Biosciences. UV Live Dead
staining reagent was included in surface and transcription factor stains (Life
Technologies, ThermoFisher, Waltham, MA), with the exception of stains for cell sorting
in which efluor780 Live/Dead stain was used. CD1d tetramer loaded with PBS-57 was
provided by the National Institutes of Health (NIH) tetramer facility (Emory University
Vaccine Center, Atlanta, GA).
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For nuclear transcription factor staining, cells were surface stained as above, after
which they were fixed overnight using the Foxp3 transcription factor staining buffer set
(EBiosciences, ThermoFisher, Waltham, MA). The next day, cells were washed, blocked
with rat IgG, and stained with anti-PLZF (9E12) (Biolegend) and RORγt (Q31-378) (BD
Biosciences), and Ki67 (Biolegend). After staining, cells were washed, resuspended, and
data were immediately collected on a LSRII flow cytometer (BD Biosciences, Franklin
Lake, NJ) and analyzed with FlowJo software (FlowJo LLC).

3.5.3 In vitro proliferation of sorted NKT cells
Splenocytes were enriched for NKT cells using the STEMCELL EasySep CD4+
negative selection kit according to the manufacturer’s instructions. After which, cells
were stained with Live/Dead efluor780 (EBiosiences), anti-TCRβ, CD11b, CD8, Nkp46,
ICOS and NRP-1, and the addition of CD1d/PBS-57 loaded-tetramer. NKT cells were
sort-purified using fluorescent activated cell sorting (FACS Aria III). Cell purity for all
sorts was between 80% and 95%. After sorting, cells were stained with Viotracker blue
for 30min. Subsequently, 40,000 cells/well were placed in modified Click’s culture
medium (5% FBS, 2mM glutamine, Pen/Strep, 50µM 2-mercaptoethanol, 20µg/mL
gentamycin) and incubated on anti-CD3 (5 g/ml) coated plates in the presence of
soluble CD28 (1 g/ml) at 37 oC and 5% CO2. 72 h later, supernatants were harvested
and analyzed via ELISA (Biolegend and R&D systems).
After culture, supernatants were harvested and media replaced with cold PBS +
2% FBS. Cells were harvested from each well and stained with propidium iodide for
108

quantification of live/dead. Harvested cells were immediately analyzed on a MACSQuant
Vyb flow cytometer. All data was analyzed using FlowJo Software (FlowJo LLC).

3.5.4 BrdU incorporation
Bromodeoxyuridine was resuspended in PBS at 10mg/mL. Mice were injected
with 1mg 24 hrs prior to the scheduled end-point. A second injection was administered
i.p. 4hrs prior to harvest. Cells were surface stained as above, then fixed in 1% PFA
overnight. The next day, the BD Biosciences BrdU staining and fixation kit was used
according to manufacturer’s instructions to prepare the cells for the transcription factor
stain. Antibodies used in these experiments were anti-BrdU, anti-PLZF, anti-RORγt and
anti-SLAMf6.

3.5.5 Statistics
All animal experiments were conducted in a non-randomized and non-blinded
fashion. Statistical analyses were performed using an unpaired T test, multiple T tests, or
2-way ANOVA where appropriate. In all cases, tests were considered significant when p
≤ 0.05. All groups were shown to have similar variance in distribution.

Sample size

estimates were based on previous experience. When data were combined from multiple
different experiments, data were first normalized to the C57BL/6 reference strain in each
experiment. Normalization was accomplished by dividing each data point in an
experiment by the average of the C57BL/6 response in that experiment. All statistical
analyses were performed using Graph Pad Prism (GraphPad Software, San Diego, CA).
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3.8 Figures

FIGURE 3-1: SLAMf6 expression marks proliferating thymic NKT2 and NKT17
subsets.

C57BL/6 thymocytes were harvested and iNKT cells identified using CD1dtetramer/PBS57 and TCRβ. iNKT cell subsets were identified using transcription factors
PLZF and RORγt as indicated in the colored boxes A). Thymus NKT2 and NKT17
subsets are highly proliferative in comparison to their NKT1 counterparts. Upper:
Representative contour plot demonstrating gating strategy to identify NKT cell subsets
and median fluorescence intensity of Ki67 on iNKT cell subsets. Lower: Quantification
of the frequency of Ki67 expression in distinct iNKT subsets. Statistical analysis was
performed using multiple t tests followed by the Holm-Sidak multiple comparisons test.
****p ≤ 0.0001 B). Increased SLAMf6 expression on Ki67+ iNKT cells. Upper:
Representative contour plots of thymus iNKT cells stained with SLAMf6 Lower:
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Quantification of the frequency of Ki67+ cells expressing SLAMf6. Data are
representative of 2 separate experiments. Statistical analysis was performed using an
unpaired t test ****p ≤ 0.0001
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FIGURE 3-2: SLAMf6high iNKT cells are more proliferative than SLAMf6low
iNKT cells.

C57BL/6 splenic SLAMf6high and SLAMf6low iNKT cells were sorted, plated at equal
numbers, and stimulated with anti-CD3 and CD28 for 72hrs. A). Representative flow
cytometry gating for sorting iNKT cell subsets. SLAMf6high cells encompass NKT2 and
NKT17 cells while SLAMf6low populations are NKT1 and NKT17 cells. B).
Representative flow cytometry of live iNKT cells recovered after sorting SLAMf6 low and
SLAMf6high iNKT cells. Middle: Quantification of live cell counts recovered. Right:
Representative flow cytometry histograms of iNKT cells stained with Viotracker and
mean fluorescence intensity of either isotype or anti-CD3 stimulated SLAMf6high or
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SLAMf6low iNKT cells. Data is representative of 3 separate experiments. Statistical
analysis was performed using one-way ANOVA followed by Tukey’s multiple
comparison test. *** p ≤ 0.001, **** p ≤ 0.0001
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FIGURE 3-3: SLAMf6highPLZFhigh iNKT cells preferentially expand after in vivo
activation.

C57BL/6 mice were treated with either vehicle or αGalCer for 72h. A). All iNKT cells in
the spleen after in vivo αGalCer stimulation express high levels of SLAMf6.
Representative flow cytometry of SLAMf6, SLAMf1, and SLAMf3 expression of iNKT
cells in vehicle treated (heavy dark line), and αGalCer treated (shaded histogram)
C57BL/6 mice. Middle: SLAM receptor staining on conventional T cells treated with or
without αGalCer. Data is representative of 3 separate experiments. Right: Median
fluorescence intensity of SLAMf1, SLAMf3, and SLAMf6 on splenic iNKT cells in
naïve (day 0), and αGalCer treated (day 3 and 5) mice. All data is representative of 2
separate experiments at each time point. Statistical analysis was performed using twoway ANOVA followed by Tukey’s multiple comparison test. **** p ≤ 0.0001 B).
Expansion of iNKT2-like cells in the spleen after administration of αGalCer.
Representative flow cytometry of iNKT cell subsets after gating on SLAMf6high and
SLAMf6low populations before (left) and after αGalCer challenge (right). C).
Incorporation of BrdU in iNKT cell subset 72h after αGalCer administration. Upper:
Representative flow cytometry of BrdU+ iNKT cells stained with either isotype control
(black) or anti-BrdU (red). Conventional T cell BrdU incorporation is shown for
comparison (right). Lower: Representative flow cytometry of PLZFhigh iNKT cells
incorporating BrdU. SLAMf6+ iNKT cell incorporation of BrdU is shown at right.
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FIGURE 3-4: SLAMf6 deficiency abrogates NKT2 and NKT17 cell proliferation.

C57BL/6 naïve splenocytes were harvested, and NKT cells identified using CD1dtetramer/PBS57 and TCRβ. ICOShighNRP-1high and ICOSlowNRP-1low iNKT cells were
sorted and plated in equal numbers on anti-CD3 with CD28 for 72hrs. SLAMf6 deficient
ICOShighNRP-1high iNKT cells have a defect in cell growth after stimulation. Left:
Representative flow cytometry of live C57BL/6 (top) and B6.SLAMf6-/- (bottom) iNKT
cells 72hrs after stimulation. Right: Live cell number of C57BL/6 versus B6.SLAMf6-/iNKT cells recovered. Data is representative of 2 separate sorts. Live cell numbers are the
combined numbers of two separate experiments normalized to the B6 control. Statistical
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analysis was performed using a 2-way ANOVA followed by Sidak multiple comparison
test. ***p ≤ 0.001. All C57BL/6 and SLAMf6-/- mice were females aged 7-10wks.
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SUPPLEMENTAL FIGURE 3-1: Sorting iNKT cells using SLAMf6 or ICOS and
NRP-1 surrogate markers yielded iNKT cells with 78.4-96.6% purity.

A). Representative post-sort analysis sorting iNKT cells using CD1d-tetramer/PBS57 and
SLAMf6high and SLAMf6low. B). Representative post-sort analysis sorting iNKT cells
using CD1d-tetramer/PBS57 and ICOShighNRP-1high and ICOSlowNRP-1low in both
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C57BL/6 mice (top) and B6.SLAM6-/- mice. Data is representative of 2 experiments for
each sort. All mice were female and age matched between 7-10wks.

SUPPLEMENTAL FIGURE 3-2: BALBc SLAMf6high splenic iNKT cells are more
proliferative than SLAMf6low iNKT cells.

BALBc splenocytes were harvested, sorted after first gating on iNKT cells using CD1dtetramer/PBS57 and TCRβ, then on levels of SLAMf6. Cells were plated in equal
numbers on anti-CD3 with CD28 for 72hrs Left: Representative flow cytometry of live
iNKT cells after 72hrs. Right: Proliferation of BALBc iNKT cell SLAMf6high and
SLAMf6low iNKT cells as indicated by Viotracker blue proliferation dye. MFI is reported
for the anti-CD3 and CD28 stimulated and the isotype control. Data is representative of
one experiment. BALBc female mice aged 20wks were used.
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SUPPLEMENTAL FIGURE 3-3: Kinetics of iNKT cell expansion.

C57BL/6 mice were challenged with αGalCer. At each time-point the number of liver
iNKT cells were identified using CD1d-tetramer/PBS57 and TCRβ. Data is the
cumulative numbers of 3 separate experiments. C57BL/6 female mice aged 10-14wks
were used.
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SUPPLEMENTAL FIGURE 3-4: C57BL/6 and B6.SLAMf6-/- iNKT cells express
similar levels of PLZF.

Naïve thymic (left) and spleen (right) iNKT cells were identified using CD1dtetramer/PBS57 and TCRβ. The mean fluorescence intensity of PLZF was determined on
total iNKT cells and each iNKT cell subset. Data is representative from 1 experiment.
Statistical analysis was performed using multiple t test and Holm-Sidak multiple
comparisons test. All mice were female aged 14wks.
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4.1. Abstract
Invariant NKT (iNKT) cells are tissue-resident innate-like T cells critical to the
host immune response. We previously identified a 6.6 Mbp region on chromosome 1 as a
major regulator of iNKT cell number and function in C57BL/6 and 129X1/SvJ mice.
Here, we fine-mapped this locus by assessing the iNKT cell response to alphagalactosylceramide (αGalCer) in a series of B6.129 congenic lines. This analysis revealed
the presence of at least two genetic elements that regulate iNKT cell cytokine production
in response to αGalCer. While one of these genetic elements mapped to the B6.129c6
interval containing Slam genes, the dominant regulator in this region mapped to the 0.14
Mbp B6.129c3 interval. In addition, we found that numbers of thymic iNKT cells and DP
thymocytes were significantly lower in B6.129c3 mice, indicating that this interval also
regulates iNKT cell development. Candidate gene analysis revealed a 5-fold increase in
Fcgr3 expression in B6.129c3 iNKT cells, and we observed increased expression of
FcγR3 protein on B6.129c3 iNKT cells, NK cells, and neutrophils. These data identify
the B6.129c3 interval as a novel locus regulating the response of iNKT cells to
glycosphingolipid, revealing a link between this phenotype and a polymorphism that
regulates Fcgr3 expression.
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4.2. Introduction
Semi-invariant iNKT cells comprise an unusual innate-like T cell subset that
plays significant roles in the host immune response to bacterial and viral pathogens
(Behar and Porcelli, 2007; Godfrey and Rossjohn, 2011; Gumperz and Brenner, 2001).
iNKT cells recognize glycolipids and glycosphingolipids presented by the MHC class Ilike molecule CD1d (Kawano et al., 1997; Pellicci et al., 2009; Spada et al., 1998). The
prototypical glycosphingolipid agonist alpha-galactosylceramide (αGalCer) is structurally
similar to glycosphingolipids from Bacteroides fragilis (Wieland Brown et al., 2013) and
is a potent activator of iNKT cells (Borg et al., 2007; Kawano et al., 1997; Kawano et al.,
1998; Koch et al., 2005; Takahashi et al., 2000). Upon activation by αGalCer presented
by CD1d, iNKT cells rapidly produce large amounts of chemokines and cytokines
(Coquet et al., 2008; Gumperz et al., 2002; Yoshimoto and Paul, 1994) and contribute to
an orchestrated activation of both innate and adaptive immune cells including dendritic
cells, macrophages, and natural killer (NK) cells (Carnaud et al., 1999; Eberl and
MacDonald, 2000; Hermans et al., 2003; Kitamura et al., 1999; Sada-Ovalle et al., 2008).
The iNKT cell subset, therefore, is uniquely poised to shape the quality and magnitude of
the developing host immune response.
Invariant NKT cell number and function varies dramatically among mice of
different genetic backgrounds. Wild-derived inbred strains (e.g., PWD/PhJ, Cast/EiJ)
have barely detectable numbers of iNKT cells (Borg et al., 2014; Chen et al., 2012), and
there is significant strain-dependent variability even among common laboratory inbred
strains (Chen et al., 2012; Gombert JM, 1996; Hammond et al., 2001; Lee et al., 2015;
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Rymarchyk et al., 2008). Accumulating evidence suggests that the genetic background
has a significant influence on the role of iNKT cells in the host immune response. For
example, iNKT cells are critical in the clearance of the opportunistic pathogen
Pseudomonas aeruginosa from the lung in BALB/cJ mice, but are dispensable in
C57BL/6J mice (Benoit et al., 2015). Similarly, pathology in iNKT cell-deficient mice
infected with Borrelia burgdorferi manifests as joint inflammation in BALB/c mice
(Tupin et al., 2008) and as myocarditis in C57BL/6J mice (Olson et al., 2009). Therefore,
a thorough understanding of the genetic determinants that regulate iNKT cell
development and function is necessary to understand the role of iNKT cells in the host
immune response.
Numerous reports have described polymorphic genetic loci that regulate iNKT
cell number and function (Aktan et al., 2010; Araujo et al., 2000; Borg et al., 2014;
Esteban LM, 2003; Fletcher et al., 2008; Jordan et al., 2007b; Wesley et al., 2007; Zhang
et al., 2003). We and others have identified a region on chromosome 1 that regulates
iNKT cell development and the response to αGalCer (Aktan et al., 2010; Gombert JM,
1996; Jordan et al., 2007b; Rocha-Campos et al., 2006). We previously demonstrated that
iNKT cells in 129X1/SvJ mice produced significantly lower amounts of cytokine after
αGalCer challenge than did iNKT cells in C57BL/6J mice. Using B6.129 congenic mice,
we identified the genetic interval spanning from rs222297065 to D1MIT115 (Chr1:
171.03 - 177.68 Mbp) as a regulator of the response of iNKT cells to in vivo αGalCer
challenge (Aktan et al., 2010). This ~6.6 Mbp locus is densely populated with numerous
immunologically relevant genes, including signaling lymphocyte activation markers
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(SLAMs) that modulate iNKT cell development and function (Griewank et al., 2007).
Interestingly, this locus overlaps extensively with several autoimmune susceptibility loci
(Edberg et al., 2002; Morel et al., 2001; Wandstrat et al., 2004) and there are numerous
reports of an association between iNKT cell numbers and autoimmunity (Baxter et al.,
1997; Cardell, 2006; Esteban et al., 2003; Gombert JM, 1996).
To refine this interval and identify candidate genes that regulated the
responsiveness of iNKT cells to αGalCer, we generated additional B6.129 subcongenic
lines with overlapping intervals. Here, we report the mapping of the iNKT cell response
to αGalCer to a minimal 0.14 Mbp interval (Chr1: 171.032-171.170) containing 4 genes
and 2 microRNAs. In addition, we found that this interval regulates total thymocyte
numbers and total iNKT cell number. Finally, we identify Fcgr3 as a possible candidate
iNKT cell regulatory gene due to the association of increased iNKT cell FcγR3
expression and impaired response of iNKT cells to αGalCer stimulation observed in
B6.129c3 mice.
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4.3. Results
4.3.1 Refinement of the 129X1/SvJ interval on chromosome 1
We previously reported that a 6.6 Mbp genetic region on chromosome 1
containing the Slam genes regulated iNKT cell function (Aktan et al., 2010). Given
previous reports that SLAMf1 and SLAMf6 are required for iNKT cell development and
the Slam genes have been reported to regulate thymic iNKT cell numbers (Aktan et al.,
2010; Jordan et al., 2011), we hypothesized that polymorphisms in one or more of the
Slam genes are responsible for the differences in the iNKT cell response to αGalCer
between C57BL/6 and 129X1/SvJ mice. To test this hypothesis, we generated 4
subcongenic strains: B6.129c2, B6.129c3, B6.129c4, and B6.129c6 with overlapping
129X1/SvJ intervals ranging from 0.14 Mbp to 1.1 Mbp that spanned the centromeric
region of the B6.129c1 interval containing Slam family genes (Figure 1a). Mapping of
the 129 derived-interval boundaries (Figure 1b) revealed that B6.129c2 and B6.129c6
strains possess Slam family genes derived from 129X1/SvJ, while B6.129c3 and
B6.129c4 strains possess Slam family genes derived from C57BL/6J.

4.3.2 Invariant NKT cell cytokine production in response to αGalCer maps to a
0.14Mbp region on chromosome 1
To determine which 129X1/SvJ intervals regulate the iNKT cell response to
glycolipid, we assessed serum IFNγ and IL-4 cytokine levels after administration of
αGalCer to C57BL/6 and B6.129 congenic strains. This analysis revealed that each of the
tested B6.129 congenic strains exhibited significantly reduced levels of serum cytokines
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in comparison to the B6 control (Figure 2a). To determine whether this decrease in
αGalCer-induced cytokine was due to reduced production by iNKT cells, we evaluated
IFNγ and IL-4 production by CD1dtetramer/PBS57-gated cells in response to αGalCer
using intracellular staining and flow cytometry (Figure 2b). Consistent with the reduced
serum cytokine production in the B6.129 congenic strains in response to αGalCer
administration, we observed significantly lower levels of iNKT IFN- and IL-4
production in B6.129c2, B6.129c3, and B6.129c4 strains as compared to the B6 parental
strain (Figure 2b). These data indicated that the dominant regulator of iNKT cell cytokine
production in response to GalCer mapped to the minimal 0.14 Mbp B6.129c3 interval.
Interestingly, examination of the cytokine production in B6.129c6 mice revealed
an intermediate phenotype. iNKT IFN-γ and IL-4 production in B6.129c6 mice were
significantly higher in comparison to B6.129c3 mice, while B6.129c6 IFN-was
significantly lower in comparison to B6 parental mice (Fig. 2b). B6.129c6 IL-4 was also
lower than B6 mice, although this reduction did not reach statistical significance
(p=0.0880) (Figure 2b). Together, these data indicated the presence of at least two genetic
elements in the B6.129c2 region that regulate iNKT cell cytokine production in response
to αGalCer: a dominant regulator mapping to the 0.14 Mbp B6.129c3 interval that did not
contain Slam genes, and a second subdominant regulator mapping to the B6.129c6
interval containing Slam genes.
Differences in in vivo iNKT cell cytokine production could be the result of an
iNKT cell-intrinsic phenomenon, or from differences in antigen processing and
presentation. To determine whether the difference in iNKT cell cytokine production was
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an iNKT-intrinsic phenomenon, we directly compared cytokine production from purified
B6 and B6.129c3 iNKT cells after stimulation. Equal numbers of sorted splenic iNKT
cells from B6 WT and B6.129c3 mice were stimulated with anti-CD3 and anti-CD28,
after which supernatants were analyzed for cytokine and chemokine production. We
observed a significant reduction in cytokines and chemokine secretion from B6.129c3
iNKT cells compared to their B6 counterparts (Figure 3). Taken together, these data
indicate that one or more of the genes contained within the B6.129c3 interval regulates
iNKT cell cytokine production through an iNKT-intrinsic process.

4.3.3 Reduced numbers of thymic iNKT cells in B6.129c3 mice
Since it has been previously reported that the Nkt1 locus that encompasses the
B6.129c3 congenic interval regulates thymic iNKT cell number (Jordan et al., 2007b), we
asked whether this phenotype could be mapped to the B6.129c3 interval. A comparison of
thymic iNKT cell numbers revealed a significant reduction in B6.129c3 thymic iNKT
cells compared to their B6 counterparts (Figure 4a). Further analysis revealed that there
was no significant difference in the overall frequency of thymic iNKT cells (data not
shown), and that the decrease in thymic iNKT cell number in B6.129c3 mice was
associated with a decrease in total thymocyte number (Figure 4a). Specifically, we
observed a specific decrease in the number of DP, but not DN, CD4 or CD8 SP, B6.129c3
thymocytes. These data suggest that the B6.129c3 interval indirectly regulates iNKT cell
development through its influence on the DP stage of thymocyte development.
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Accumulating data suggest that there is significant strain-dependent variation in
the distribution of iNKT cell subsets (Lee et al., 2013; Lee et al., 2015). Therefore, we
considered the possibility that the iNKT cell-intrinsic differences in cytokine production
was due to regulation of the distribution of iNKT cell subsets by the B6.129c3 congenic
interval. iNKT1, iNKT2, and iNKT17 subsets were identified according to their
expression of PLZF and RORγt (Lee et al., 2013) (Figure 4b, left). Examination of the
frequency and number of thymic iNKT cell subsets in C57BL/6 and B6.129c3 mice
revealed a decrease in the numbers of iNKT1 and iNKT2 cells, consistent with the
decrease in total iNKT cell numbers (Figure 4b). The iNKT17 subset also showed a trend
toward lower numbers in the B6.129c3 mouse, albeit not significantly lower. Taken
together, these results suggest that the B6.129c3 interval regulates the number of thymic
iNKT cells but does not significantly affect the distribution of iNKT cell subsets.

4.3.4 Increased expression of FcγR3 on B6.129c3 iNKT cells
The B6.129c3 congenic interval contains 4 genes and two micro-RNAs (Table 1).
Examination of gene expression data using the Immgen database (Heng et al., 2008)
suggested that one of the genes, Mpz (myelin protein zero) is not expressed in leukocytes,
and we confirmed this data using PCR and gene-specific primers (data not shown).
We next investigated whether one or more of the remaining three genes, Fcgr3
(Fc receptor, IgG, low affinity III), Cfap126 (cilia and flagella associated protein), or
Sdhc (succinate dehydrogenase complex c), were differentially expressed in B6.129c3
naive mice compared to C57BL/6 controls. We sorted splenic iNKT cells from C57BL/6
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and B6.129c3 mice and used quantitative PCR to assess gene expression. Interestingly,
we found that Fcgr3 gene expression was significantly higher (5.5-fold change) on
B6.129c3 iNKT cells compared to their B6 counterparts (Figure 5a). In contrast, no
significant differences in Cfap126 or Sdhc expression were observed between the two
strains.
We next determined whether the increase in Fcgr3 gene expression correlated
with an increase in protein expression on the surface of B6.129c3 iNKT cells. Similar to a
previous report (Kim et al., 2006), we observed a very low, but detectable level of FcγR3
expression on naïve iNKT cells from B6.129c3 mice as well as from parental strain
129X1/SvJ mice (Figure 5b). To confirm the increased expression of FcγR3 in B6.129c3
mice, we also assessed expression on neutrophils that express significant levels of this
protein. This analysis similarly revealed increased FcγR3 expression on neutrophils from
both B6.129c3 and 129X1/SvJ parental mice (Fig. 5b). We then compared iNKT FcγR3
expression between αGalCer-treated B6 and B6.129c3 mice to determine if activation
altered the relative expression. While this analysis revealed significantly greater FcγR3
on iNKT cells and NK cells, the relative expression difference was similar to that seen in
naïve mice (Fig. 5c). Together, these data suggest that one or more polymorphisms in the
B6.129c3 interval regulates Fcgr3 gene and cell surface expression, and identifies Fcgr3
as a candidate gene responsible for regulation of the iNKT cell responsiveness to
αGalCer.
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4.4. Discussion
The ability of iNKT cells to rapidly produce large amounts of cytokines and
chemokines in response to pathogens puts them in a unique position to shape the
developing host immune response. In this context, natural genetic variants that modulate
iNKT cell function could have significant downstream effects on the host immune
response to pathogens. We recently demonstrated that two seemingly conflicting reports
regarding the role of iNKT cells in the clearance of Pseudomonas aeruginosa from the
lung (Nieuwenhuis et al., 2002; Stevenson et al., 1995) could be reconciled when genetic
background was taken into consideration (Benoit et al., 2015). For reasons that are still
unclear, BALB/c iNKT cells make a significant contribution to the host immune response
after P. aeruginosa infection, but B6 iNKT cells do not. The strain-dependent role of
iNKT cells in bacterial clearance was associated with strain-dependent differences in the
response of lung iNKT cells to αGalCer. Elucidation of genetic variants that regulate
iNKT cell function is necessary to understand their role in the host immune response.
Invariant NKT cell number, function, and tissue-specific homing varies widely
among inbred strains of mice (Aktan et al., 2010; Lee et al., 2013; Lee et al., 2015;
Rymarchyk et al., 2008) and several polymorphic loci that regulate iNKT cell number
have been identified (Aktan et al., 2010; Borg et al., 2014; Esteban et al., 2003; Fletcher
et al., 2008; Gombert JM, 1996; Jordan et al., 2004; Jordan et al., 2007b; Rocha-Campos
et al., 2006). In an investigation into the role of iNKT cells in type 1 diabetes, it was
reported that autoimmune-prone non-obese diabetic (NOD) mice possessed very low
numbers of iNKT cells (Baxter et al., 1997; Godfrey et al., 1997; Gombert JM, 1996). A
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genetic locus, Nkt1, regulating the number of thymic iNKT cells was identified and
mapped to a distal region on chromosome 1 (D1MIT15 - D1MIT155). The Nkt1 locus
contained several immunologically relevant genes, including CD247, FcγR2b, FcγR3,
and the Slam family of receptors including Slamf1 and Slamf6 (Esteban LM, 2003;
Rocha-Campos et al., 2006), which are required for iNKT cell development in the thymus
(Griewank et al., 2007). A subsequent report implicated Slamf1 in the regulation of
thymic iNKT cell numbers as well as iNKT IL-4, but not IFN, production (Jordan et al.,
2007b). Here, we have refined this locus further and have found evidence suggesting the
presence of at least two regulators of NKT cell number and function. Our data suggest
that Slam genes may not be the major regulators of the iNKT cell response to αGalCer in
this region. Although B6.129c6 mice that possess the Slam129 and FcgrB6 alleles exhibited
reduced IFN- and IL-4 production in comparison to B6 mice, the dominant effect was
observed in B6.129c3 and B6.129c4 mice that possess SlamB6 and Fcgr129 alleles.
Conversely, the observation that B6.129c6 iNKT cell cytokine production was
significantly greater than their B6.129c3 counterparts in both cytokines measured is
consistent with the presence of an additional gene or genetic modifier regulating this
phenotype. Together, these data suggest the possibility that there are multiple genetic
elements in the larger B6.129c2 interval that regulate the function of iNKT cells: a novel
genetic element that we identified in the B6.129c3 interval, and one or more genes (most
likely Slam genes) or genetic modifiers in the B6.129c6 interval.
We identified Fcgr3 as a candidate gene in regulating the iNKT cell response.
FcR3 (CD16) is an activating receptor that binds IgG and signals through an immune137

tyrosine activation domain (ITAM) and is highly expressed on monocytes, macrophages,
neutrophils, and NK cells (Kim et al., 2006; Nimmerjahn and Ravetch, 2007). We found
that FcγR3 gene and protein expression was significantly increased on iNKT cells, NK
cells, and neutrophils from B6.129c3 and 129X1/SvJ parental mice compared to
C57BL/6 controls. The underlying basis for this differential expression is still unclear. A
comparison of Fcgr3 promoter sequence (as defined by the Eukaryotic promoter
database, (Dreos et al., 2017) between C57BL/6 and 129S1/SvImJ strains revealed no
nucleotide differences. However, over 100 upstream variants were identified, suggesting
the possibility that a substitution in an enhancer element could affect expression (data not
shown).
Here, we confirm previous reports that iNKT cells express low, but detectable
levels of FcR3 (Araujo et al., 2011; Kim et al., 2006; Park-Min et al., 2007). These
previous reports demonstrate that engagement of Fc receptors can significantly modulate
iNKT cell function. In one study, intravenous Ig (IVIG) treatment was found to exert
some of its effect through its action on iNKT cells (Park-Min et al., 2007), and IVIG
administration to C57BL/6 mice resulted in diminished iNKT cell activation. Coadministration of αGalCer and IVIG resulted in severely reduced IL-4 and IFNγ
production compared to mice treated with αGalCer alone, and this inhibition was
dependent on FcγR3 (Araujo et al., 2011). Our finding that increased expression of
FcγR3 on B6.129c3 iNKT cells is associated with decreased cytokine production is
consistent with these data, although it remains unclear whether there is increased FcγR3
signaling in B6.129c3 iNKT cells.
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Given the association of increased Fcgr3 in B6.129c3 mice and alterations in
thymocyte number, it is possible that the NKT cell-intrinsic changes in function stem
from differences in development. FcγR3 is expressed on developing thymocytes
(Rodewald et al., 1992; Sandor et al., 1994) and Fcɛr1γ, which encodes the signaling
chain of FcγR3 contributes to TCR signaling (Flamand et al., 1996; Shores et al., 1997).
Interestingly, Fcɛr1γ was recently demonstrated to be over-expressed in NKT1 cells, and
deletion of Fcɛr1γresulted in altered frequencies of NKT1 and NKT2 subsets (Georgiev
et al., 2016). Whether the impaired iNKT cell function observed in B6.129c3 mice is
associated altered FcγR3 and/or Fcɛr1γ signaling will require further study.
Although our results suggest a role for Fcgr3 in the regulation of iNKT cells, we
cannot rule out the other genetic elements that lie within the B6.129c3 region. We did not
observe differences in gene expression of Sdhc or Cfap126 genes on sorted splenic iNKT
cells. Mutations in the Sdha, b, and c genes have been linked to susceptibility to
mitochondrial disorders (Renkema et al., 2015). Cfap126 has been shown to have a
function on pancreatic β cells (Bader et al., 2016), but studies of this gene on iNKT cells
have not been performed. Several microRNAs have had reported roles in regulating
iNKT cell development, including the Let-7 family of microRNAs (Burocchi et al., 2015;
Fedeli et al., 2016; Frias et al., 2017). The microRNA Mir6546 present in the B6.129c3
interval appears to be rare (Castellano and Stebbing, 2013; Meunier et al., 2013) and its
function has not been studied in immune cells. Therefore, although this interval contains
multiple genes and genetic elements, the most likely iNKT cell regulator within our
interval is Fcgr3.
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In summary, we have fine-mapped a locus that regulates the iNKT cell response
to the agonist glycolipid αGalCer. Our findings suggest that the previously described
Nkt1 locus contains at least two genetic elements that regulate NKT cell number and
function, and that the dominant regulator in the region maps to a congenic interval
containing Fcgr3, identifying it as a probable candidate gene for these phenotypes.
Further characterization of this genetic locus and of the Fc receptor signaling pathway
will aid in our understanding of the role of iNKT cells in host immunity.
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4.5. Materials and Methods
4.5.1 Mice and Reagents
C57BL/6J mice were purchased from The Jackson Laboratory (Bar Harbor, ME).
B6.129c1 mice were described previously (Wandstrat et al., 2004), and B6.129c2,
B6.129c3, B6.129c4 and B6.129c6 strains were generated by backcrossing B6.129c1
mice to C57BL/6J mice, and intercrossing the heterozygous progeny. Offspring in which
recombinants were identified were backcrossed B6 to allow for the generation of
homozygous congenic lines. The congenic interval boundaries were determined using
primer sets designed to amplify across informative insertions/deletions and SNPs (Table
2). PCR products were sequenced to confirm boundaries. All mice were age and sex
matched as indicated in the figure legends. All mice were housed and bred in the specific
pathogen-free barrier facility at the University of Vermont. The alpha-galactosylceramide
(Avanti Polar Lipids, Alabaster, Alabama) was prepared as described previously (Aktan
et al., 2010) and administered i.p. at indicated doses in a 100µL volume. All procedures
involving animals were approved by the University of Vermont Institutional Animal Care
and Use Committee.

4.5.2 Serum cytokine analysis
Mice were bled via cardiac puncture, after which serum was collected and frozen
at -20°C until analysis by ELISA according to the manufacturer’s instructions
(Biolegend, San Diego, CA, BD Biosciences, Franklin Lakes, NJ).
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4.5.3 Flow cytometry
Splenocytes and thymocytes were obtained by gently pressing through a 70 m
nylon mesh. RBCs were lysed using Gey’s solution. Cells were stained at 4°C in PBS +
2% FBS containing 0.2% sodium azide for 30 min., after which they were washed and
resuspended in PBS + 1% PFA. Abs used in these experiments were anti-CD4 (RM4-5),
CD45 (30-F11), TCRβ (H57-597), NK1.1 (PK136), CD8 (53-6.7) (Biolegend), and
CD11b (M1/70), CD16/32 (2.4G2) and CD19 (6D5) (BD Biosciences). UV Live Dead
staining reagent was included in all experiments (Life technologies, ThermoFisher, Grand
Island, NY). CD1d tetramer loaded with PBS-57 was provided by the National Institutes
of Health (NIH) tetramer facility (Emory University Vaccine Center, Atlanta, GA).
For intracellular cytokine staining (ICS), cells were isolated from the spleen as
described above and stained with Ab to surface markers. In every ICS experiment, cells
were analyzed directly ex vivo without further treatment. After washing in staining buffer,
cells were fixed with 4% PFA for 30 min at 4oC. After washing in permeabilization
buffer (0.1% saponin, 1% FCS, 0.1% sodium azide in PBS), cells were stained with antiIL-4 (11B11) and anti-IFNγ (XMG1.2) or isotype-matched control antibodies. All
intracellular antibodies were from Biolegend. Data was collected on an LSRII (BD
Biosciences) and analyzed using FlowJo software (FlowJo LLC, Ashland, OR).
Purified CD16/32 (Clone 93) (Biolegend) was used in all samples prior to the
addition of Abs to block nonspecific Ab binding, except for samples in which FcγR3
expression was being assessed. In those cases, Fc block was not performed, and
conjugated anti-CD16/CD32 (2.4G2) (BD Biosciences, San Jose, CA) was added to the
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surface stain master mix. As controls for FcγR3 staining and to control for the addition of
conjugated 2.4G2 on all Fc receptors, cells were stained with unconjugated 2.4G2 Ab in
order to block receptors and subsequently stained with conjugated 2.4G2. As a separate
control, cells were stained with unconjugated 2.4G2 Ab and subsequently stained with an
isotype matched control (IgG2a, Biolegend).
For nuclear transcription factor staining, cells were surface stained as above, after
which they were fixed overnight using the Foxp3 transcription factor staining buffer set
(eBiosciences/ThermoFisher, San Diego, CA). The next day cells were washed, blocked
with rat IgG, and stained with anti-PLZF (9E12) and RORγt (Q31-378) (BD). After
staining, cells were washed, resuspended, and data were immediately collected on a
LSRII flow cytometer (BD Bioscience) and analyzed with FlowJo software (FlowJo
LLC).

4.5.4 Cell isolation and culture for ex vivo cytokine analysis
Splenocytes were enriched for CD4 T cells by depletion of CD8 (53-6.7), CD11b
(M1/70), MHCII (M5-114) (BioXcell, West Lebanon, NH) with anti-rat and anti-mouse
IgG magnetic beads (Qiagen, Hilden, Germany). After enrichment, cells were stained
with anti-TCRβ, CD1dtetramer/PBS57, and DAPI, and iNKT cells were purified by
fluorescence activated cell sorting (FACS Aria III). Cell purity for all sorts was between
83% and 97%. After sorting, cells were placed in modified Click’s culture medium (5%
FBS, 2mM glutamine, Pen/Strep, 50µM 2-mercaptoethanol, 20µg/mL gentamycin) and
incubated on anti-CD3 (5 g/ml) and anti-CD28 (1 g/ml)-coated plates at 37oC and 5%
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CO2. 72 h later, supernatants were harvested and analyzed via Milliplex assay, according
to the manufacturer’s instructions (EMD Millipore, Darmstadt, Germany). The milliplex
kits used were the Mouse cytokine/chemokine magnetic bead panel followed by a custom
kit containing GM-CSF, IFNγ, IL-2, IL-4, IL-5, IL-10, IL-13, and IL-17.

Quantitative real-time PCR
Sorted iNKT cells were washed in cold PBS, after which cell pellets were snap
frozen and kept at -80oC until RNA was isolated. RNA isolation was performed using the
RNeasy Micro kit according to the manufacturer’s instructions (Qiagen, Hilden,
Germany). cDNA was synthesized using Superscript III (ThermoFisher, San Diego, CA).
Mpz and Pcp4l-1 expression was evaluated by PCR using the gene specific primers: Mpz
forward

5’-CGGACAGGGAAATCTATGGTGC-3’,
Pcp4l-1

TGGTAGCGCCAGGTAAAAGAG-3’.

reverse
forward

5’5’-

ATGAGCGAGCTTAACACCAAA-3’, reverse 5’- CTGCCAGGCTTCCCTTTTTC-3’
using cDNA derived from central nervous system tissue (a gift from D. Krementsov,
University of Vermont). Expression of Fcgr3, Sdhc, and Cfap126 was evaluated using
Assay on Demand (AOD) Taqman probes (Life Technologies, Carlsbad, CA) according
to the manufacturer’s instructions. qPCR assay on demand (AOD) was run using the
Perfecta qPCR SuperMix (Quanta Biosciences, Beverly MA). Samples were incubated
with UNG SuperMIX at 45°C for 5m, then denatured initially at 95°C for 3m, followed
by: 95°C denaturation for 15 s, and a combined 60°C annealing and extension step for
45s for 40 cycles. Fold change was calculated by determining 2-∆∆CT using mouse β-Actin
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as the endogenous control. Data was collected on an ABI Prism 7900HT Sequence
Detection System.

4.5.5 Statistics
All animal experiments were conducted in a non-randomized and non-blinded
fashion. One way-ANOVA, two-way ANOVA, or unpaired T tests were used where
appropriate. ANOVA post-hoc analysis comparisons were made using Dunnett’s test,
Sidak’s multiple comparisons test, Tukey’s multiple comparisons test, or Holm-Sidak’s
multiple comparisons test where appropriate. In all cases, tests were considered
significant when p ≤ 0.05. All groups were shown to have similar variance in distribution.
Sample size estimates were based on previous experience. In Figure 2B, 3 mice were
excluded from the analysis due to poor αGalCer injections. When data were combined
from multiple different experiments, data were first normalized to the C57BL/6 reference
strain in each experiment. Normalization was accomplished by dividing each data point
in an experiment by the average of the C57BL/6 response in that experiment. All
statistical analysis was performed using Graph Pad Prism (GraphPad Software, San
Diego, CA).
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4.8. Figures

FIGURE 4-1: Fine-mapping of the B6.129c1 congenic interval

A). (Left) Schematic of the chromosome 1 congenic intervals used in this study. Black
regions denote C57BL/6 derived regions, white denotes 129X1/SvJ derived regions, and
the cross-hatched region is either C57BL/6 or 129X1/SvJ derived (undefined). For
reference, the Slam family genes are denoted in red and the Fc receptor gene family is
denoted in green. B). Number of protein-coding genes predicted in each subcongenic
interval. Lower: Reference SNPs that define boundaries for each congenic line on the
centromeric and telomeric ends.
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FIGURE 4-2: Regulation of αGalCer-induced iNKT cell cytokine production
maps to a 0.14 Mbp region on chromosome 1

A). Decreased serum cytokine in B6.129 congenic mice in response to αGalCer. Blood
was collected from B6 or B6.129 congenic mice 2 h after αGalCer administration. Serum
cytokine levels were assessed using ELISA. Statistical analysis was performed using 2way ANOVA followed by Tukey’s multiple comparisons test, *p ≤ 0.05, **p ≤ 0.01,
***p ≤ 0.001, ****p ≤ 0.0001 B). Top: Representative intracellular staining of cytokineproducing iNKT cells in response to GalCer. Splenocytes were isolated 2 h after
αGalCer administration. iNKT cells were identified using CD1d-tetramer/PBS57 and
TCRβ. The percentages of iNKT cells expressing cytokines were determined using an
isotype control for each mouse. Lower: Decreased iNKT cell cytokine production in
B6.129 congenic mice in response to αGalCer. The data represent the relative level of
iNKT cell cytokine production. Data are the combined data from 5 separate experiments
using female mice 8 -14wks of age and are presented as the mean ± s.d. All mice were
age-matched to controls in each experiment. Statistical analysis was performed using 2way ANOVA followed by Tukey’s multiple comparison test. * = comparison of B6 to
B6.129 congenics. # = comparison of B6.129c3 to B6.129 congenics. *,# p ≤ 0.05, **, ## p
≤ 0.01, ***, ### p ≤ 0.001, ****, ####p ≤ 0.0001.
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FIGURE 4-3: Reduced cytokine production in B6.129c3 is iNKT cell-intrinsic.
iNKT cells were sorted from C57BL/6 or B6.129c3 splenocytes.

Cells were stimulated using anti-CD3 and anti-CD28 for 72 h, after which supernatants
were analyzed using Milliplex. Data represent the cumulative results from 3 separate
experiments using 8 - 11week old female mice. Mice were age-matched in each
experiment. Statistical analysis was performed using a 2-way ANOVA followed by the
Holm-Sidak multiple comparison test and is reported as the mean normalized
concentration ± s.d. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001
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FIGURE 4-4: iNKT cell numbers in the thymus are regulated by the B6.129c3
interval.

A). iNKT cell (left), total thymocyte (middle), thymocyte subset (right) numbers were
compared between C57BL/6 and B6.129c3 mice. B). No significant difference in the
distribution of thymic iNKT subsets between B6 and B6.129c3 mice. iNKT cell subsets
were identified based on PLZF and RORt expression as indicated by colored boxes
(left). Cumulative numbers of iNKT cell subsets are shown (right). Data represent the
cumulative results of 4 separate experiments using 9 – 13 week old female mice. Mice
were age matched in each experiment. Statistical analysis was performed using an
unpaired T-test. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ .001
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FIGURE 4-5: Increased Fcgr3 gene and protein expression on B6.129c3 iNKT
cells.

Increased Fcgr3 gene and protein expression on B6.129c3 iNKT cells. A) Increased
Fcgr3 gene expression in B6.129c3 splenic iNKT cells. Spleen iNKT cells were sorted
using CD1d tetramer/PBS-57 for RNA isolation. Gene expression was determined using
quantitative PCR. Data is reported as the fold change relative to B6. B) Increased cell
surface protein expression of FcγR3 on naive B6.129c3 iNKT and neutrophils.
Representative flow cytometry histograms show expression levels of FcγR3 on B6.129c3
iNKT cells (upper) and neutrophils (lower). Shaded dark histograms represent cells
161

blocked with unconjugated 2.4G2 Ab and subsequently stained with conjugated isotype
control. Heavy lined histograms are cells stained with conjugated 2.4G2 Ab. The
numbers represent the median fluorescence intensity (MFI). Graphs depict the
normalized MFI of 2.4G2 relative to the B6 control. Data represents the mean ± s.d. and
is the cumulative data from 2 separate experiments of female mice aged 6-8wks. C)
Increased cell surface protein expression of FcγR3 on αGalCer treated B6.129c3 iNKT
and NK cells. Shaded dark histograms represent cells blocked with unconjugated 2.4G2
Ab and subsequently stained with conjugated isotype control. Heavy lined histograms are
cells stained with conjugated 2.4G2 Ab. The numbers represent the median fluorescence
intensity (MFI). Graphs depict normalized MFI of 2.4G2 relative to the B6 control. Data
represents the mean ± s.d. and is representative data from 2 independent experiments
using 10 or 14 week old female mice. Statistics were performed using a 1-way ANOVA
and followed by a post-hoc comparison to B6 controls using Dunnett’s test. **p ≤ .01,
****p ≤ 0.0001
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Table 1. Genetic elements within the B6.129c3 interval.
Gene

Name

Position

Fcgr3

Fc receptor, IgG
low affinity III

171.051-171.064

Cfap126

Cilia and
flagella
associated
protein

171.113-171.126

Mpz

Myelin protein
zero

171.150-171.161

Sdhc

Succinate
dehydrogenase
complex subunit
C

171.127-171.150

microRNA

171.064
171.079

Mir6546
GM27844

Nonsynonymous
SNPs
12

1

1

2

n.a.

Gene positions were determined according to Ensembl release 90. Structural
variants, missense variants, and splice variants were determined using the
Mouse Phenome Database, Sanger 4 and NCBI dbSNP databases. SNP values
are those that result in amino acid changes between C57BL/6 and
129S1/SvImJ. The B6.129c3 interval boundaries are on chromosome 1
location 171.032 Mbp to 171.170 Mbp.
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CHAPTER 5: CONCLUSIONS AND FUTURE DIRECTIONS

Initial identification of an unusual T cell expressing the Vβ8 invariant TCR was
performed in 1987 (Budd et al., 1987; Fowlkes et al., 1987). It was not until 8 years later
that these cells were defined as a new αβ T cell subset called natural killer T cells
(Macdonald, 2007). In the 8 years that it took for iNKT cells to be agreed upon, reports
were generated showing how these cells did not fit the definition of a traditional T cell.
Immunologists describe new cells by defined functional or phenotypic markers that fit
into a defined “box”. Natural killer T cells, so named due to both function and the
markers they express, do not fit into a classic box for immune cells, and have been
challenging to define. In some instances, they are protective, in others, pathogenic
(Crosby and Kronenberg, 2018). After activation they make numerous Th1, Th2, Th17,
or Treg cytokines, displaying a diverse repertoire of function. Some iNKT cells are
cytotoxic, some undergo activation induced cell death, and others are long lived. It can be
safely said that iNKT cells do not fit into any one box, but many, bridging both innate
and adaptive immunity and showcasing incredibly versatility to contribute to host
immunity (Godfrey et al., 2004) (Figure 5-1).
Diversity within the iNKT cell lineage and among the iNKT cell subsets may be
important for the ways in which iNKT cells contribute to host immune responses. Since
the SLAM receptors are heterogeneously expressed on iNKT cells (Aktan et al., 2010),
we can envision a scenario in which interactions with a SLAM family receptor
expressing antigen presenting cell can change the functionality of the iNKT cell subsets.
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It has already been shown that SLAMf6 crosslinking on an APC and iNKT cell are
required for proper IFNγ and IL-4 production (Baglaenko et al., 2017). There is evidence
to suggest that a certain subset of dendritic cells can present antigen that results in a Th1
Th2 bias, but the mechanisms for how this presentation could be specific to a certain
iNKT cell subset is currently unknown (Arora et al., 2014). Does SLAM family receptor
crosslinking induce the production of cytokines from the APC, which then changes how
the iNKT cell responds? Does one subset lead to increased kinetics of immune cell
activation or vice versa? Is the repertoire of SLAM family receptors on the APC just as
important for effector function as the SLAM family receptor repertoire on the iNKT cell?
These questions, given our added knowledge of iNKT cell subsets, and our contribution
of how SLAM family receptors modulate iNKT cell subset responses, can now be
addressed.
An interesting point of further investigation is whether organ specific iNKT
cells can be stimulated with different agonists at the same time. While this is likely a
normal occurrence within different tissues with self-glycolipids, it would be interesting to
“polarize” iNKT cell subsets into distinct cytokine or cytotoxic inducing cells for
different disease treatments. We already know that there are distinct ligands that can
induce IFNγ versus IL-4, such as αGalCer and OCH respectively (Sullivan et al., 2010;
Velmourougane et al., 2009), but how these agonists induce specific iNKT cell TCRβ
chains and subsets leading to cytokine production has only recently been investigated
(Cameron, Godfrey 2015). Several of these agonists are being used as adjuvants to induce
a more robust immune cell activation, but these treatments have only shown modest
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ability to increase iNKT cell responses in humans (Giaccone et al., 2002; Ishikawa et al.,
2005). One interesting line of study would be to deliver specific iNKT cell agonists that
would activate distinct iNKT cell subsets.
Our data shows that the SLAM family expression patterns on iNKT cell subsets
are determined during thymic development. This suggests additional programming and
lineages where iNKT cells are “destined” to become NKT1, NKT2, or NKT17. Before
the work shared in this dissertation, the role of SLAM receptors in this process had not
been studied in detail.
Recent reports identifying determinants of iNKT cell development give us some
clues into how iNKT subset cell development could be regulated. Programming of the
NKT cell lineage is said to require signaling through Id (inhibitor of DNA binding and
differentiation) and E proteins (helix-loop-helix proteins), which serve as transcriptional
regulators, often functioning to antagonize the function of the other (Roy and Zhuang,
2018). Downstream of Id proteins is a protein responsible for the induction of the master
transcription factor PLZF termed Egr2 (early growth response protein). Surprisingly,
SLAMf6 has been shown to induce expression of PLZF via the regulation of Egr2 after
ligation of the TCR on iNKT cells (Tuttle et al., 2018). E proteins, which function
downstream from the TCR and SLAM family receptor crosslinking, can bind to the PLZF
promoter, while Id proteins inhibit this interaction, indicating that these proteins can aid
in the regulation of iNKT cell PLZF expression. Intriguingly, Id proteins are required for
the development of iNKT cells, but appear to inhibit production of the SAP dependent
innate-like Vγ1.1Vδ6.3 subset as well as NKT2 cells (D'Cruz et al., 2014; Verykokakis et
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al., 2010), indicating that Id proteins are intimately involved in the developmental
programs of these subsets.
Additional data suggest that upon deletion of SAP in a Vα14 transgenic model,
development of NKT2 cells is decreased while NKT17 cells are increased and NKT1
cells are not affected, indicating separate, but overlapping signaling mechanisms in iNKT
cell development (Michel et al., 2016). Taken together, we speculate that these reports
suggest that TCR ligation in concert with SLAM family receptor crosslinking potentiates
separate signaling cascades involving E and Id protein regulation of iNKT cell subset
development. Our findings that SLAMf6 specifically regulates NKT2 and NKT17, but
not NKT1, subsets suggests that signaling from distinct SLAM family receptors
augments TCR signals in developing iNKT cells that ultimately shape their
differentiation fate. The molecular nature of these signaling mechanisms during iNKT
cell development currently needs more investigation.
In Chapter 3, we found that NKT2 and NKT17 cells were more proliferative
than their NKT1 counterparts. We show that after αGalCer-mediated expansion of iNKT
cells, there appears to be an influx of NKT2-like iNKT cells. There are several
possibilities for this observation. First, this phenotype could result from the upregulation
of PLZF and Tbet after activation in the predominant spleen NKT1 cell population,
resulting in their acquisition of an NKT2 phenotype. Alternatively, proliferative NKT2
cells could be preferentially expanding and repopulating the peripheral organs, thereby
outnumbering NKT1 cells 3 days after activation. The first model would suggest that the
iNKT cell subset definitions based on PLZF, Tbet, GATA3 and RORγt expression are
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useful only in resting iNKT cell populations, and suggests a degree of plasticity in the
iNKT cell population. Although plasticity among conventional T helper cells is now
recognized (Gagliani et al., 2015), the degree of plasticity exhibited by the different NKT
cell subsets remains unknown. The second model suggests that the ratio of iNKT cell
subsets changes after activation due to the repopulation of the periphery with NKT2 cells,
possibly from cells repopulating the thymus. We know that repeated administration of
GalCer over a period of weeks reveals the presence of IL-10-producing NKT cells
(NKT10) (Sag et al., 2014). Whether this results from the differentiation of NKT cells or
the preferential expansion of a small pre-existing NKT10 subset remains to be
determined. Interestingly in Chapter 3, supplemental figure 1, we show that the number
of iNKT cells in the spleen returns toward baseline levels 5 days after activation with
GalCer. An analysis of the iNKT cell subsets at this time-point could reveal whether a
different subset is present or whether immature NKT2 precursors then convert into NKT1
and NKT2 cells once in the tissue. In the future, adoptive transfers of different iNKT cell
subsets marked with congenic markers will be necessary to address these questions in the
future. In summary, while NKT1, NKT2, and NKT17 subsets are apparent during
development (Lee et al., 2013), these definitions are less apparent after peripheral
activation, indicating a degree of plasticity that has yet to be determined.
We show in Chapter 4 that Slam haplotypes play a role in regulating iNKT cell
subset development and function (Aktan et al., 2010; DeVault et al., 2018). However, we
found the altered iNKT cell function in B6.129 congenic mice was not primarily due to
allelic differences among the Slam genes. Rather, we identified Fcgr3 as a potential
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candidate in this regulation. Investigation into the exact mechanisms that control Fcgr3
regulation of iNKT cells are currently ongoing in the lab. Our data in Chapter 4 suggested
both Fcgr3 and SLAM family receptors as regulating the iNKT cell responses. While
these genes do not necessarily have to work together and epistatic mechanisms may be at
play, there is some speculation that these receptors do work in concert. Interestingly,
FcγR3 appears to signal synergistically with the CD2 receptor in activation of NK cells
(Liu et al., 2016). SLAM family receptors are said to be a part of the CD2 family of
receptors and SLAMf2 can bind hetero-typically to CD2 (van der Merwe et al., 1995).
We therefore speculate that SLAM family receptors, such as CD2, could act as coreceptors for activation and signaling through FcγR3. Additionally, this data could
suggest that other SLAM family receptors, such as SLAMf4 (which binds to SLAMf2),
may have the ability to bind to CD2, allowing for crosslinking and co-receptor functions
of CD2 to FcγR3.
The work provided within this dissertation could have broader implications for
human innate T cell biology. The data we show here raise questions as to whether similar
SLAM family receptor modulation is present on human innate-like T cells and iNKT
cells. Data has suggested evidence for human iNKT cell subsets, although they are less
defined than those in the mouse (Zeng et al., 2013). To date, a complete analysis of
SLAM family receptor expression on human iNKT, γδT, or MAIT cells has not been
completed. We have already discussed that there are SAP dependent γδ T cells and iNKT
cells (Nichols et al., 2005a; Verykokakis et al., 2010). MAIT cells do not appear to be
SAP dependent, but they do express SLAM receptors. Humans happen to have a high
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number of MAIT cells that are dependent on B cells and the gut microbiome for
development (Chandra and Kronenberg, 2015). While subsets of MAIT cells have not
been determined, SLAM family receptors could play a role in MAIT cell effector
functions, especially upon engagement with an APC. Similar SLAM family receptor
analyses on γδ T cells and ILC populations are currently being performed in the lab,
suggesting that differing SLAM receptor expression mediating function are not unique to
iNKT cell subsets. Instead, these patterns lend diversity to many different innate-like
cells in the mouse, and potentially, the human.
With the renewed interest in human cancer immunotherapies, iNKT cell subsets
are being thought of as important cells in modulating the immune response toward solid
tumors such as melanoma and neuroblastoma (Wolf et al., 2018). We show in Chapter 3
that NKT2 and NKT17 cells are more proliferative than their NKT1 counterparts,
indicating that some iNKT cell subsets may be better for expansion for immunotherapy.
In addition, the repertoire of cytotoxic iNKT cells to kill tumors, as well as cytokine
producing iNKT cells (if they are not the same), should be taken into consideration. In a
search of clinical trials at the US National Library of Medicine website, there were over
30 NKT cell related clinical trials (as of 09/20/2018). In most of these studies, iNKT cells
were isolated from the patient, expanded in vitro, and then given back to the same patient
to stimulate the immune system, especially NK cells and cytotoxic T cells. Some of the
data from completed trials show that expanded iNKT cells produced only IFNγ and no
IL-4 or IL-10 (Exley et al., 2017), suggesting that only one type of iNKT cell may have
been expanded. Although this difference in cytokine production may have been from the
170

specific expansion protocol (Exley et al., 2014), it would be beneficial to trials in the
future to determine whether subsets of iNKT cells can be expanded independently for
differential cytokine production, and to potentially, aid in stimulating different parts of
the immune system for treating different types of cancers.
In conclusion, this dissertation reveals specificity of distinct regulatory
mechanisms on iNKT cell subsets provided by the SLAM family of signaling receptors
as well as a novel candidate gene, Fcgr3 (Figure 5-1). This work provides context for the
diverse and specific functions of iNKT cell mediated host immunity.
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Summary

FIGURE 5-1: Diversity SLAM family receptor expression patterns controls the
development and function of iNKT cell subsets
A). The regulatory mechanisms behind how iNKT cells produce a myriad of cytokines, home to
particular tissues, and how particular SLAM family receptors specifically function on iNKT cells
have not been elucidated B). Upon the identification of iNKT cell subsets, information about the
tissue localization and specific cytokine production of these cells began to emerge. In this
dissertation, we reveal specific SLAM family receptor expression profiles on distinct iNKT cell
subsets. C). SLAMf6, highly expressed on NKT2 and NKT17 cells, specifically affects the
cytokine production and cell growth of NKT2 and NKT17 cells, but not that of NKT1 cells. This
work identifies SLAM family receptors as crucial regulators of NKT cell subset development and
function.
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